Track market-moving stories before they get noisy

SummaryPalantir Technologies is rated Strong Buy due to accelerating revenue growth, expanding margins, and a durable AI-as-a-service moat.PLTR's model should benefit when AI infrastructure costs fall; its margins are already widening while peers’ compress, backed by deep government and commercial client entrenchment.Quarterly revenue grew 93% YoY, U.S. commercial revenue surged 149%, and adjusted operating margin expanded to 62%, outperforming software peers.Despite high multiples (115x earnings, 53x sales), PLTR's premium is justified by compounding growth, proven execution, and significant forward contract value.JasonDoiy/iStock Unreleased via Getty Images

Palantir Technologies Inc. (PLTR) has had one of the strangest years in the market. Its revenue grew 93% last quarter, its earnings more than doubled, and management raised its full-year guidance for the third time. The stock has gone

88 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

New York, New York--(Newsfile Corp. - October 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026 in the securities class action first filed by the Firm.

SO WHAT: If you purchased Ensign securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ensign class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Ensign's business model depends on the systematic and widespread neglect of elderly people who live in its facilities, including those with needs for high levels of care; (2) Ensign's abuse and neglect includes not giving residents enough food, medical attention, or even basic toiletries as well as failing to respond to residents in clear distress, which has resulted in resident deaths; (3) Ensign uses self-reporting measures as a way to cover up that it systematically neglects patients; (4) Ensign defrauds Medicaid and Medicare by taking federal funds to help patients who need high levels of care, and then neglecting those same patients; (5) Ensign falsifies the number of hours that Certified Nursing Assistants spend with residents; (6) Ensign engages in an illegal scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, its facilities; (7) Ensign materially understated the reputational and litigation exposure that comes with a dangerous, abhorrent, and illegal business model; and (8) as a result, defendants' statements about Ensign's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ensign class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319514

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - October 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Bank of America Corporation (NYSE: BAC) resulting from allegations that Bank of America may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Bank of America securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/bank-of-america-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: After market hours on October 13, 2026, Fox Business published an article entitled "Bank of America hit with $1.2B in penalties over money laundering compliance failures". The article stated that the "Treasury Department announced approximately $1.21 billion in penalties against Bank of America over longstanding anti-money laundering failures and U.S. sanctions violations." Further the article stated that regulators "found the bank failed to adequately investigate trillions of dollars in potentially suspicious transactions despite knowing about significant compliance deficiencies."

On this news, Bank of America stock fell 4.7% on October 14, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319498

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation

Updated first-line data for olomorasib, an investigational therapy targeting KRAS G12C-mutant NSCLC, to be featured in a rapid oral presentation

Updated Phase 3 data for selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant MTC to be shared in a proffered paper

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 in Madrid, Spain. Highlights include new Phase 1 data in platinum-sensitive ovarian cancer (PSOC) for sofetabart mipitecan (Sofe-M), Lilly's investigational FRα-targeting antibody-drug conjugate (ADC), in combination with bevacizumab, along with updated findings for olomorasib, Retevmo (selpercatinib), and Verzenio (abemaciclib) in lung, thyroid, and breast cancers, respectively. 

Key Presentation Highlights:

Sofetabart mipitecan (Sofe-M; FRα-targeting ADC): A rapid oral presentation on first Phase 1 data for sofetabart mipitecan plus bevacizumab in patients with PSOC. These data support the ongoing Phase 3 clinical trial of Sofe-M in PSOC.

Olomorasib (investigational KRAS G12C inhibitor):
A rapid oral presentation on an updated integrated analysis from the Phase 1/2 LOXO-RAS-20001 trial and the safety lead-in portion of the Phase 3 SUNRAY-01 trial, assessing olomorasib in combination with chemoimmunotherapy (pembrolizumab, pemetrexed, and platinum) as potential first-line treatments for patients with advanced/metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC). These data support the ongoing Phase 3 clinical trial of olomorasib in first-line KRAS G12C-mutant lung cancer.

Retevmo (selpercatinib; RET kinase inhibitor): A proffered paper presentation on updated results from the Phase 3 LIBRETTO-531 study of selpercatinib versus cabozantinib or vandetanib (C/V) in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer (MTC). These data have supported global approvals of Retevmo in this treatment setting.

Verzenio (abemaciclib; CDK4/6 inhibitor): A rapid oral presentation on overall survival data from the Phase 3 postMONARCH trial of abemaciclib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor and endocrine therapy. These data support the abemaciclib plus imlunestrant results in the EMBER-3 trial and add to the evidence-based practice of switching endocrine therapy and CDK4/6 inhibitor at progression in metastatic breast cancer.

"Lilly's presentations at ESMO reflect both the breadth of our oncology portfolio and the focus behind it: following compelling science wherever it has the potential to change care," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "We're especially encouraged by the data we're sharing for sofetabart mipitecan in platinum-sensitive ovarian cancer, which build on what we've seen with this medicine in platinum-resistant disease and mark a critical step forward as we advance the ongoing Phase 3 FRAmework-01 study across both settings. Our updated first-line data for olomorasib in KRAS G12C-mutant lung cancer are very promising, with clinical activity and a safety profile consistent with earlier findings, which reinforce the importance of targeted therapy for patients from the outset of their treatment journey. Alongside new data in thyroid and breast cancers, these presentations represent meaningful momentum toward improving care for people with cancer."

A full list of abstract titles and viewing details are listed below:

Abstract Title

Author

Presentation
Type/#

Session Title

Session Date/Time

(CET)

Sofe-M (sofetabart mipitecan; investigational ADC targeting FRα):

Model-informed Phase 3 dose
selection for antibody-drug conjugate
(ADC) sofetabart mipitecan (Sofe-M):
First prospective application of a
clinical utility index (CUI) 

Jean-
Sebastien
Frenel

Poster
#1016P

Poster display
session

Friday, October 23

15:15-16:00

Efficacy and safety
of sofetabart mipitecan (Sofe-M), a
folate receptor alpha (FRα) targeting
antibody drug conjugate (ADC), plus
bevacizumab in recurrent platinum
sensitive ovarian cancer (PSOC) 

Chrisann Kyi

Rapid oral
#1246RO

Rapid oral 2:
Gynecological
cancers

Saturday, October 24

8:30-10:00

Sofetabart mipitecan (Sofe-M) in
patients ≥65 y with platinum-resistant
and -sensitive ovarian cancer
(PROC/PSOC) from the first-in-human
phase 1 study 

Ana Oaknin

Poster
#1288P

Poster display
session

Monday, October 26

12:00-12:45

Olomorasib (investigational KRAS G12C inhibitor)

First-line (1L) olomorasib +
chemoimmunotherapy (Chemo-IO) in
KRAS G12C-mutant NSCLC: Updated
results from the LOXO-RAS-20001 and
SUNRAY-01 trials 

Marcelo V.
Negrao

Rapid oral
#2652RO

Rapid oral 2:
NSCLC, metastatic

Sunday,

October 25

8:30-10:00

First-line (1L) olomorasib +
pembrolizumab in KRAS G12C-mutant
NSCLC: Updated results from LOXO-
RAS-20001 and SUNRAY-01 

Melissa L.
Johnson

Poster
#2683P

Poster display
session

Monday, October 26

12:00-12:45

Retevmo (selpercatinib; RET kinase inhibitor)

Updated results of randomized Phase
3 study of selpercatinib vs
cabozantinib or vandetanib (C/V) in
advanced, kinase inhibitor-naïve, RET-
mutant medullary thyroid cancer
(MTC) 

Jaume
Capdevila

Proffered paper
#4208O

Proffered paper:
NETs and
endocrine tumors

Monday, October 26

10:15-11:45

Verzenio (abemaciclib; CDK4/6 inhibitor)

Association of p27 V109G SNP zygosity
with outcomes
and abemaciclib treatment effect in
HR+, HER2– high-risk early breast
cancer: results from monarchE 

Miguel
Quintela-
Fandino

Poster
#4498P

Poster display
session

Friday, October 23

15:15-16:00

Overall survival from the Phase
3 postMONARCH trial of abemaciclib +
fulvestrant vs placebo + fulvestrant for
HR+, HER2– advanced breast cancer
following progression on a prior
CDK4/6 inhibitor + endocrine therapy 

Kevin Kalinsky

Rapid oral
#1RO

Rapid oral 1:
Breast cancer,
advanced stage

Saturday, October 24

10:15-11:45

Three-month persistence and
adherence to adjuvant abemaciclib in
high-risk HR+, HER2– early breast
cancer: real world data from ABSIDE-S 

Isabel Blancas
López-Barajas

ePoster
#1933eP

ePoster session

Friday, October 23

8:00

Treatment persistence and clinical
characteristics in patients with HR+,
HER2–, high-risk early breast cancer
(EBC) treated with abemaciclib: A
multi-country real-world study  

Hitomi Sakai

ePoster
#615eP

ePoster session

Friday, October 23

8:00

For more information on Lilly's oncology pipeline, click here.

About Sofetabart Mipitecan
Sofetabart mipitecan (Sofe-M; LY4170156) is composed of an Fc-silent, folate receptor alpha (FRα) specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker (PSARlink). Sofe-M was designed to target FRα across all expression levels with an improved therapeutic index. FRα is a cell-surface glycoprotein encoded by the gene FOLR1 that binds to the essential nutrients folic acid and reduced folates, bringing them into cells to facilitate cell division and growth.1,2 FRα is overexpressed in many solid tumors such as ovarian and endometrial cancers.1,3,4 Sofe-M has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for platinum-resistant ovarian cancer (PROC) and is currently being evaluated in the Phase 3 FRAmework-01 trial. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT – lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).

About Olomorasib
Olomorasib (LY3537982) is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. KRAS is the most common oncogene across all tumor types, and KRAS G12C mutations occur in 13% of patients with non-small cell lung cancer (NSCLC), and 1–3% of patients with other solid tumors.5 Olomorasib is a highly potent covalent inhibitor with potential for greater than 90% target occupancy, which may allow for safer combinations with less toxicity.6

Olomorasib is currently being studied in KRAS G12C-mutant cancers in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced NSCLC, in combination with immunotherapy for the treatment of resected and unresectable NSCLC, and as monotherapy and in combinations in other advanced solid tumors (NCT06119581, NCT06890598, and NCT04956640).

About Retevmo
Retevmo (selpercatinib, formerly known as LOXO-292) (pronounced reh-TEHV-moh) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity. Retevmo may affect both tumor cells and healthy cells, which can result in side effects. RET-driver alterations are predominantly mutually exclusive from other oncogenic drivers. Retevmo is a U.S. FDA-approved oral prescription medicine, 120 mg or 160 mg dependent on weight (<50 kg or ≥50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity.7

INDICATIONS FOR RETEVMO (selpercatinib)
RETEVMO is a kinase inhibitor indicated for the treatment of:

Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy IMPORTANT SAFETY INFORMATION FOR RETEVMO (selpercatinib)

Hepatotoxicity: Serious hepatic adverse reactions occurred in 4.6% of patients treated with Retevmo. Increased aspartate aminotransferase (AST) occurred in 62% of patients, including Grade 3 or 4 events in 11% and increased alanine aminotransferase (ALT) occurred in 58% of patients, including Grade 3 or 4 events in 13%. Monitor ALT and AST prior to initiating Retevmo, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose, or permanently discontinue Retevmo based on severity.

Severe, life-threatening, and fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with Retevmo. ILD/pneumonitis occurred in 3% of patients who received Retevmo, including 0.3% with Grade 3 or 4 events, and 0.2% with fatal reactions. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold Retevmo and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Withhold, reduce dose, or permanently discontinue Retevmo based on severity of confirmed ILD.

Hypertension occurred in 43% of patients, including Grade 3 hypertension in 20% and Grade 4 in one (0.1%) patient. Overall, 6.4% had their dose interrupted, 1.5% had their dose reduced, and 0.2% discontinued Retevmo for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications. Do not initiate Retevmo in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating Retevmo. Monitor blood pressure after 1 week, at least monthly thereafter, and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue Retevmo based on severity.

Retevmo can cause concentration-dependent QT interval prolongation. An increase in QTcF interval to >500 ms was measured in 8% of patients and an increase in the QTcF interval of at least 60 ms over baseline was measured in 22% of patients. Retevmo has not been studied in patients with clinically significant active cardiovascular disease or recent myocardial infarction. Monitor patients who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure. Assess QT interval, electrolytes, and thyroid-stimulating hormone (TSH) at baseline and periodically during treatment, adjusting frequency based upon risk factors including diarrhea.

Correct hypokalemia, hypomagnesemia, and hypocalcemia prior to initiating Retevmo and during treatment. Monitor the QT interval more frequently when Retevmo is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Withhold and dose reduce or permanently discontinue Retevmo based on the severity.

Serious, including fatal, hemorrhagic events can occur with Retevmo. Grade ≥3 hemorrhagic events occurred in 4.3% of patients treated with Retevmo including 4 (0.5%) patients with fatal hemorrhagic events, including cerebral hemorrhage (n=2), tracheostomy site hemorrhage and hemoptysis (1 each). Permanently discontinue Retevmo in patients with severe or life-threatening hemorrhage.

Retevmo can cause hypersensitivity, including severe skin reactions such as Stevens-Johnson Syndrome. All grade hypersensitivity occurred in 6% of patients receiving Retevmo, including Grade 3 in 2%. The median time to onset was 1.9 weeks (range: 5 days to 6.5 years). Signs and symptoms of hypersensitivity included fever, rash and arthralgias or myalgias with concurrent decreased platelets or transaminitis. Stevens-Johnson Syndrome has been observed in the post-marketing setting. Discontinue Retevmo in patients with Stevens-Johnson Syndrome. If hypersensitivity occurs, withhold Retevmo and begin corticosteroids at a dose of 1 mg/kg prednisone (or equivalent). Upon resolution of the event, resume Retevmo at a reduced dose and increase the dose of Retevmo by 1 dose level each week as tolerated until reaching the dose taken prior to onset of hypersensitivity. Continue steroids until patient reaches target dose and then taper. Permanently discontinue Retevmo for recurrent hypersensitivity.

Tumor lysis syndrome (TLS) occurred in 0.9% of patients with medullary thyroid carcinoma and 0.3% of patients with non-small cell lung cancer receiving Retevmo. Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Closely monitor patients at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated.

Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, Retevmo has the potential to adversely affect wound healing. Withhold Retevmo for at least 7 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of Retevmo after resolution of wound healing complications has not been established.

Retevmo can cause hypothyroidism. Hypothyroidism occurred in 15% of patients treated with Retevmo; all reactions were Grade 1 or 2. Hypothyroidism occurred in 15% of patients (59/390) with thyroid cancer and 14% of patients (65/467) with other solid tumors including NSCLC. Monitor thyroid function before treatment with Retevmo and periodically during treatment. Treat with thyroid hormone replacement as clinically indicated. Withhold Retevmo until clinically stable or permanently discontinue Retevmo based on severity.

Based on data from animal reproduction studies and its mechanism of action, Retevmo can cause fetal harm when administered to a pregnant woman. Administration of selpercatinib to pregnant rats during organogenesis at maternal exposures that were approximately equal to those observed at the recommended human dose of 160 mg twice daily resulted in embryolethality and malformations. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Retevmo and for 1 week after the last dose. There are no data on the presence of selpercatinib or its metabolites in human milk or on their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with Retevmo and for 1 week after the last dose.

Slipped capital femoral epiphysis/slipped upper femoral epiphysis in pediatric patients (SCFE/SUFE) occurred in 1 adolescent (2.8% of 36 patients) receiving Retevmo in LIBRETTO-121 and 1 adolescent patient (0.5% of 193 patients) receiving Retevmo in LIBRETTO-531. Monitor patients for symptoms indicative of SCFE/SUFE and treat as medically and surgically appropriate.

Severe adverse reactions (Grade 3-4) occurring in ≥20% of patients who received Retevmo in LIBRETTO-001 were hypertension (20%), diarrhea (6.2%), prolonged QT interval (5%), fatigue (4.7%), musculoskeletal pain (4.1%), dyspnea (4.1%), hemorrhage (3.9%), abdominal pain (3.5%), vomiting (2.9%), urinary tract infection (2.2%), nausea (1.9%), headache (1.8%), edema (1.3%), decreased appetite (0.9%), constipation (0.8%), rash (0.8%), and dizziness (0.5%).

Severe adverse reactions (Grade 3-4) occurring in ≥15% of patients who received Retevmo in LIBRETTO-121 were increased weight (11%), vomiting (8%), constipation (6%), diarrhea (2.8%), nausea (2.8%), upper respiratory tract infection (2.8%), and urinary tract infection (2.8%).

Severe adverse reactions (Grade 3-4) occurring in ≥15% of patients who received Retevmo or chemotherapy with or without pembrolizumab in LIBRETTO-431 were hypertension (20% vs 3.1%), electrocardiogram QT prolonged (9% vs 0%), fatigue (3.2% vs 5%), edema (2.5% vs 0%), rash (1.9% vs 1.0%), diarrhea (1.3% vs 2.0%), abdominal pain (0.6% vs 2.0%), pyrexia (0.6% vs 0%), COVID19 infection (0.6% vs 0%), constipation (0% vs 1.0%), nausea (0% vs 1.0%), vomiting (0% vs 1.0%), and decreased appetite (0% vs 2.0%).

Severe adverse reactions (Grade 3-4) occurring in ≥10% of patients who received Retevmo in LIBRETTO-531 were (Retevmo vs cabozantinib / vandetanib) hypertension (19% vs 18%), electrocardiogram QT prolonged (4.7% vs 2.1%), fatigue (4.1% vs 9%), diarrhea (3.1% vs 8%), rash (1.6% vs 4.1%), pyrexia (1.0% vs 0%), nausea (1.0% vs 5%), dry mouth (0.5% vs 1.0%), abdominal pain (0.5% vs 2.1%), stomatitis (0.5% vs 13%), headache (0.5% vs 0%), and decreased appetite (0.5% vs 5%).

Serious adverse reactions occurred in 58% of patients who received Retevmo in LIBRETTO-001. The most frequently reported serious adverse reactions (in ≥2% of patients) were pneumonia, hemorrhage, abdominal pain, dyspnea, pleural effusion, sepsis, musculoskeletal pain, hyponatremia, vomiting, diarrhea, and increased blood creatinine. Fatal adverse reactions occurred in 3% of patients in LIBRETTO-001; fatal adverse reactions included sepsis (n=6), respiratory failure (n=5), hemorrhage (n=4), pneumonia (n=4), cardiac arrest (n=3), pneumonitis (n=2), cardiac failure (n=2), sudden death (n=1), cerebral infarction (n=1), and dyspnea (n=1).

Serious adverse reactions occurred in 42% of patients who received Retevmo in LIBRETTO-121. Serious adverse reactions occurring in more than 1 patient were vomiting and fracture (2 patients each).

Serious adverse reactions occurred in 35% of patients who received Retevmo in LIBRETTO-431. The most frequently reported serious adverse reactions (≥2% of patients) were pleural effusion and abnormal hepatic function. Fatal adverse reactions occurred in 4.4% of patients who received Retevmo in LIBRETTO-431; fatal adverse reactions included myocardial infarction (n=2), respiratory failure (n=2), cardiac arrest, malnutrition, and sudden death (n=1 each).

Serious adverse reactions occurred in 22% of patients who received Retevmo in LIBRETTO-531. The most frequent serious adverse reactions were pneumonia and pyrexia (n=3 each), and hypertension and urinary tract infection (n=2 each). Fatal adverse reactions occurred in 2.1% of patients who received Retevmo in LIBRETTO-531; fatal adverse reactions included COVID19, diabetic ketoacidosis, multiple organ dysfunction syndrome, and sudden death (n=1 each).

Common adverse reactions (all grades) occurring in ≥20% of patients who received Retevmo in LIBRETTO-001 were musculoskeletal pain (59%), edema (53%), diarrhea (52%), fatigue (49%), dry mouth (44%), hypertension (43%), abdominal pain (39%), rash (38%), nausea (36%), constipation (35%), cough (30%), headache (30%), vomiting (29%), dyspnea (28%), hemorrhage (26%), decreased appetite (23%), dizziness (22%), prolonged QT interval (21%), and urinary tract infection (20%).

Common adverse reactions (all grades) occurring in ≥15% of patients who received Retevmo in LIBRETTO-121 were musculoskeletal pain (58%), diarrhea (47%), nausea (42%), hemorrhage (39%), pyrexia (39%), abdominal pain (36%), headache (33%), vomiting (31%), fatigue (31%), cough (31%), rash (28%), coronavirus infection (28%), upper respiratory tract infection (28%), edema (25%), constipation (22%), oropharyngeal pain (22%), hypothyroidism (22%), urinary tract infection (19%), and increased weight (19%).

Common adverse reactions (all grades) occurring in ≥15% of patients who received Retevmo or chemotherapy with or without pembrolizumab in LIBRETTO-431 were hypertension (48% vs 7%), diarrhea (44% vs 24%), edema (41% vs 28%), dry mouth (39% vs 6%), rash (33% vs 30%), fatigue (32% vs 50%), abdominal pain (25% vs 19%), musculoskeletal pain (25% vs 28%), constipation (22% vs 40%), electrocardiogram QT prolonged (20% vs 1.0%), COVID19 infection (19% vs 18%), stomatitis (18% vs 16%), decreased appetite (17% vs 34%), nausea (13% vs 44%), vomiting (13% vs 23%), and pyrexia (13% vs 23%).

Common adverse reactions (all grades) occurring in ≥10% of patients who received Retevmo in LIBRETTO-531 (Retevmo vs cabozantinib / vandetanib) were hypertension (43% vs 41%), edema (33% vs 5%), dry mouth (32% vs 10%), fatigue (28% vs 47%), diarrhea (26% vs 61%), headache (23% vs 21%), rash (19% vs 27%), abdominal pain (18% vs 21%), constipation (16% vs 12%), erectile dysfunction (16% vs 0%), stomatitis (14% vs 42%), electrocardiogram QT prolonged (14% vs 13%), pyrexia (12% vs 2.1%), decreased appetite (12% vs 28%), hypothyroidism (11% vs 21%), and nausea (10% vs 32%).

Laboratory abnormalities (all grades ≥20%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-001, were increased AST (62%; 11%), decreased calcium (61%; 7%), decreased albumin (61%; 3.6%), increased ALT (58%; 13%), increased glucose (56%; 4.0%), decreased lymphocytes (56%; 22%), increased creatinine (51%; 3.6%), decreased sodium (49%; 13%), increased alkaline phosphatase (43%; 4.4%), decreased platelets (41%; 4.0%), increased potassium (39%; 3.5%), decreased glucose (39%; 1.5%), increased total cholesterol (37%; 1.7%), decreased magnesium (37%; 0.7%), decreased hemoglobin (36%; 4.1%), increased bilirubin (32%; 2.9%), decreased neutrophils (27%; 3.8%), and decreased phosphate (25%; 5%).

Laboratory abnormalities (all grades ≥15%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-121 were decreased calcium (61%; 11%), increased ALT (58%; 8%), decreased albumin (53%; 0%), increased alkaline phosphatase (50%; 0%), increased AST (50%; 2.8%), increased bilirubin (31%; 2.8%), increased cholesterol (28%, 0%), decreased magnesium (28%; 6%), increased potassium (28%; 2.8%), increased creatinine (19%, 2.8%), decreased potassium (19%, 6%), decreased sodium (17%, 0%), decreased neutrophils (40%; 8%), decreased hemoglobin (36%; 11%), increased hemoglobin (33%, 2.8%), decreased platelets (28%; 2.8%), and decreased lymphocytes (28%; 14%).

Laboratory abnormalities (all grades ≥20%; Grade 3-4) worsening from baseline in patients who received Retevmo or chemotherapy with or without pembrolizumab in LIBRETTO-431 were increased ALT (81%; 21% vs 63%; 4.1%), increased AST (77%; 10% vs 46%; 0%), decreased calcium (53%; 1.9% vs 24%; 1.0%), decreased platelets (53%; 3.2% vs 39%; 5%), decreased lymphocytes (53%; 8% vs 64%; 15%), decreased neutrophils (53%; 2.0% vs 58%; 11%), increased bilirubin (52%; 1.3% vs 9%; 0%), increased alkaline phosphatase (35%; 1.3% vs 22%; 0%), decreased sodium (31%; 3.2% vs 41%; 2.1%), decreased albumin (25%; 0% vs 5%; 0%), increased blood creatinine (23%; 0% vs 21%; 0%), decreased hemoglobin (21%; 0% vs 91%; 5%), decreased potassium (17%; 1.3% vs 15%; 1.0%), and decreased magnesium (16%; 0.6% vs 8%; 0%).

Laboratory abnormalities (all grades ≥5%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-531 (Retevmo vs cabozantinib / vandetanib) were decreased calcium (55%; 5% vs 62%; 11%), increased ALT (53%; 16% vs 72%; 7%), increased AST (47%; 5% vs 68%; 3.2%), decreased lymphocytes (41%; 18% vs 36%; 13%), increased alkaline phosphatase (37%; 6% vs 28%, 5%), increased bilirubin (32%; 1.1% vs 30%; 3.2%), decreased neutrophils (33%; 14% vs 42%; 19%), decreased platelets (28%; 1.1% vs 34%; 1.1%), increased creatinine (27%; 6% vs 16%; 8%), decreased sodium (20%; 3.2% vs 16%; 0%), decreased hemoglobin (18%; 2.1% vs 23%; 2.1%), decreased albumin (11%; 1.1% vs 7%; 0%), decreased magnesium (9%; 3.3% vs 26%; 9%), and decreased potassium (8%; 0% vs 22%; 4.4%).

Concomitant use of acid-reducing agents decreases selpercatinib plasma concentrations which may reduce Retevmo anti-tumor activity. Avoid concomitant use of proton-pump inhibitors (PPIs), histamine-2 (H2) receptor antagonists, and locally acting antacids with Retevmo. If coadministration cannot be avoided, take Retevmo with food (with a PPI) or modify its administration time (with a H2 receptor antagonist or a locally acting antacid).

Concomitant use of strong and moderate CYP3A inhibitors increases selpercatinib plasma concentrations which may increase the risk of Retevmo adverse reactions including QTc interval prolongation. Avoid concomitant use of strong and moderate CYP3A inhibitors with Retevmo. If concomitant use of a strong or moderate CYP3A inhibitor cannot be avoided, reduce the Retevmo dosage as recommended and monitor the QT interval with ECGs more frequently.

Concomitant use of strong and moderate CYP3A inducers decreases selpercatinib plasma concentrations which may reduce Retevmo anti-tumor activity. Avoid coadministration of Retevmo with strong and moderate CYP3A inducers.

Concomitant use of Retevmo with CYP2C8 and CYP3A substrates increases their plasma concentrations which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of Retevmo with CYP2C8 and CYP3A substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for CYP2C8 and CYP3A substrates provided in their approved product labeling.

Retevmo is a P-glycoprotein (P-gp) and BCRP inhibitor. Concomitant use of Retevmo with P-gp or BCRP substrates increases their plasma concentrations, which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of Retevmo with P-gp or BCRP substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for P-gp and BCRP substrates provided in their approved product labeling.

The safety and effectiveness of Retevmo have not been established in pediatric patients less than 2 years of age. The safety and effectiveness of Retevmo have been established in pediatric patients aged 2 years and older for the treatment of advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate), and locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

Monitor open growth plates in pediatric patients. Consider interrupting or discontinuing Retevmo if abnormalities occur.

No dosage modification is recommended for patients with mild to severe renal impairment (estimated Glomerular Filtration Rate [eGFR] ≥15 to 89 mL/min, estimated by Modification of Diet in Renal Disease [MDRD] equation). A recommended dosage has not been established for patients with end-stage renal disease.

Reduce the dose when administering Retevmo to patients with severe hepatic impairment (total bilirubin greater than 3 to 10 times upper limit of normal [ULN] and any AST). No dosage modification is recommended for patients with mild or moderate hepatic impairment. Monitor for Retevmo-related adverse reactions in patients with hepatic impairment.

Retevmo (selpercatinib) is available as 40 mg and 80 mg capsules, and 40 mg, 80 mg, 120 mg, and 160 mg tablets.

SE HCP ISI All_JUL2026

Please see full Prescribing Information and Instructions for Use for Retevmo.

About Verzenio (abemaciclib)
Verzenio (abemaciclib) is approved to treat people with certain HR+, HER2– breast cancers in the adjuvant and advanced or metastatic settings. Verzenio is an oral tablet taken twice daily and available in strengths of 50 mg, 100 mg, 150 mg, and 200 mg. Discovered and developed by Lilly researchers, Verzenio was first approved in 2017 and is authorized for use in more than 90 countries around the world. For full details on indicated uses of Verzenio in HR+, HER2– breast cancer, please see full Prescribing Information, available at www.Verzenio.com.

INDICATIONS FOR VERZENIO 

Verzenio (abemaciclib) is a kinase inhibitor indicated8,9:

in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. in combination with Inluriyo for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. as monotherapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. IMPORTANT SAFETY INFORMATION FOR VERZENIO (abemaciclib)
Severe diarrhea associated with dehydration and infection occurred in patients treated with Verzenio. Across five clinical trials in 3899 patients, diarrhea occurred in 81% to 90% of patients who received Verzenio. Grade 3 diarrhea occurred in 8% to 20% of patients receiving Verzenio. Most patients experienced diarrhea during the first month of Verzenio treatment. The median time to onset of the first diarrhea event ranged from 6 to 8 days; and the median duration of Grade 2 and Grade 3 diarrhea ranged from 6 to 11 days and 5 to 8 days, respectively. Across trials, 19% to 26% of patients with diarrhea required a Verzenio dose interruption and 13% to 23% required a dose reduction.

Instruct patients to start antidiarrheal therapy such as loperamide at the first sign of loose stools, increase oral fluids, and notify their healthcare provider for further instructions and appropriate follow-up. For Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization, withhold Verzenio until resolution to ≤Grade 1, and then resume Verzenio at the next lower dose.

Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with Verzenio. Across five clinical trials in 3899 patients, neutropenia occurred in 37% to 51% of patients receiving Verzenio. A Grade ≥3 decrease in neutrophil count (based on laboratory findings) occurred in 19% to 32% of patients receiving Verzenio.

Across trials, the median time to first episode of Grade ≥3 neutropenia ranged from 29 days to 34 days, and the median duration of Grade ≥3 neutropenia ranged from 10 days to 16 days.

Febrile neutropenia has been reported in <1% of patients exposed to Verzenio across trials. Two deaths due to neutropenic sepsis were observed in MONARCH 2. Inform patients to promptly report any episodes of fever to their healthcare provider.

Monitor complete blood counts prior to the start of Verzenio therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.

Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with Verzenio and other CDK4/6 inhibitors. In Verzenio-treated patients in early breast cancer (monarchE, N=2791), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%). In Verzenio-treated patients in advanced or metastatic breast cancer (N=1108) (MONARCH 1, MONARCH 2, MONARCH 3, EMBER-3), 3.2% of Verzenio-treated patients had ILD or pneumonitis of any grade: 0.5% had Grade 3 or 4, and 0.5% had fatal outcomes. Additional cases of ILD or pneumonitis have been observed in the postmarketing setting, with fatalities reported.

Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.

Withhold or reduce dose for patients who develop persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis.

Grade ≥3 increases in alanine aminotransferase (ALT) (2% to 6%) and aspartate aminotransferase (AST) (2% to 3%) were reported in patients receiving Verzenio.

Across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87 days and the median time to resolution to Grade <3 was 13 to 14 days. The median time to onset of Grade ≥3 AST increases ranged from 71 to 185 days and the median time to resolution to Grade <3 ranged from 11 to 15 days.

Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or any Grade 3 or Grade 4 hepatic transaminase elevation.

Venous thromboembolic events (VTE) were reported in 2% to 5% of patients treated with Verzenio across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3). VTE events included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, inferior vena cava thrombosis, jugular vein thrombosis, peripheral vein thrombosis and superficial vein thrombosis. In clinical trials, deaths due to VTE occurred in patients treated with Verzenio.

Verzenio has not been studied in patients with early breast cancer who had a history of VTE. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate. Dose interruption is recommended for early breast cancer patients with any grade VTE event and for advanced or metastatic breast cancer patients with a Grade 3 or 4 VTE event.

Verzenio can cause fetal harm when administered to a pregnant woman, based on findings from animal studies and the mechanism of action. In animal reproduction studies, administration of abemaciclib to pregnant rats during the period of organogenesis caused teratogenicity and decreased fetal weight at maternal exposures that were similar to the human clinical exposure based on area under the curve (AUC) at the maximum recommended human dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Verzenio and for 3 weeks after the last dose.

Verzenio can increase serum creatinine without affecting renal function. These increases were not associated with changes in glomerular function. In EMBER-3, creatinine increase occurred in 36% for all grades (Grade 3 or 4: 1.1%) of patients who received Inluriyo in combination with Verzenio. During Verzenio treatment, use alternative measures that are not based on serum creatinine to assess renal function such as BUN, cystatin C, or calculated GFR.

The most common adverse reactions (all grades, ≥10%) observed in monarchE for Verzenio plus tamoxifen or an aromatase inhibitor vs tamoxifen or an aromatase inhibitor, with a difference between arms of ≥2%, were diarrhea (84% vs 9%), infections (51% vs 39%), neutropenia (46% vs 6%), fatigue (41% vs 18%), leukopenia (38% vs 7%), nausea (30% vs 9%), anemia (24% vs 4%), headache (20% vs 15%), vomiting (18% vs 4.6%), stomatitis (14% vs 5%), lymphopenia (14% vs 3%), thrombocytopenia (13% vs 2%), decreased appetite (12% vs 2.4%), ALT increased (12% vs 6%), AST increased (12% vs 5%), dizziness (11% vs 7%), rash (11% vs 4.5%), and alopecia (11% vs 2.7%).

The most frequently reported ≥5% Grade 3 or 4 adverse reaction that occurred in the Verzenio arm vs the tamoxifen or an aromatase inhibitor arm of monarchE were neutropenia (19.6% vs 1%), leukopenia (11% vs <1%), diarrhea (8% vs 0.2%), and lymphopenia (5% vs <1%).

Lab abnormalities (all grades; Grade 3 or 4) for monarchE in ≥10% for Verzenio plus tamoxifen or an aromatase inhibitor with a difference between arms of ≥2% were increased serum creatinine (99% vs 91%; 0.5% vs <0.1%), decreased white blood cells (89% vs 28%; 19.1% vs 1.1%), decreased neutrophil count (84% vs 23%; 18.7% vs 1.9%), anemia (68% vs 17%; 1% vs .1%), decreased lymphocyte count (59% vs 24%; 13.2% vs 2.5%), decreased platelet count (37% vs 10%; .9% vs .2%), increased ALT (37% vs 24%; 2.6% vs 1.2%), increased AST (31% vs 18%; 1.6% vs .9%), and hypokalemia (11% vs 3.8%; 1.3% vs 0.2%).

The most common adverse reactions (all grades, ≥10%) observed in MONARCH 3 for Verzenio plus anastrozole or letrozole vs anastrozole or letrozole, with a difference between arms of ≥2%, were diarrhea (81% vs 30%), fatigue (40% vs 32%), neutropenia (41% vs 2%), infections (39% vs 29%), nausea (39% vs 20%), abdominal pain (29% vs 12%), vomiting (28% vs 12%), anemia (28% vs 5%), alopecia (27% vs 11%), decreased appetite (24% vs 9%), leukopenia (21% vs 2%), creatinine increased (19% vs 4%), constipation (16% vs 12%), ALT increased (16% vs 7%), AST increased (15% vs 7%), rash (14% vs 5%), pruritus (13% vs 9%), cough (13% vs 9%), dyspnea (12% vs 6%), dizziness (11% vs 9%), weight decreased (10% vs 3.1%), influenza-like illness (10% vs 8%), and thrombocytopenia (10% vs 2%).

The most frequently reported ≥5% Grade 3 or 4 adverse reactions that occurred in the Verzenio arm vs the placebo arm of MONARCH 3 were neutropenia (22% vs 1%), diarrhea (9% vs 1.2%), leukopenia (7% vs <1%)), increased ALT (6% vs 2%), and anemia (6% vs 1%).

Lab abnormalities (all grades; Grade 3 or 4) for MONARCH 3 in ≥10% for Verzenio plus anastrozole or letrozole with a difference between arms of ≥2% were increased serum creatinine (98% vs 84%; 2.2% vs 0%), decreased white blood cells (82% vs 27%; 13% vs 0.6%), anemia (82% vs 28%; 1.6% vs 0%), decreased neutrophil count (80% vs 21%; 21.9% vs 2.6%), decreased lymphocyte count (53% vs 26%; 7.6% vs 1.9%), decreased platelet count (36% vs 12%; 1.9% vs 0.6%), increased ALT (48% vs 25%; 6.6% vs 1.9%), and increased AST (37% vs 23%; 3.8% vs 0.6%).

The most common adverse reactions (all grades, ≥10%) observed in MONARCH 2 for Verzenio plus fulvestrant vs fulvestrant, with a difference between arms of ≥2%, were diarrhea (86% vs 25%), neutropenia (46% vs 4%), fatigue (46% vs 32%), nausea (45% vs 23%), infections (43% vs 25%), abdominal pain (35% vs 16%), anemia (29% vs 4%), leukopenia (28% vs 2%), decreased appetite (27% vs 12%), vomiting (26% vs 10%), headache (20% vs 15%), dysgeusia (18% vs 2.7%), thrombocytopenia (16% vs 3%), alopecia (16% vs 1.8%), stomatitis (15% vs 10%), ALT increased (13% vs 5%), pruritus (13% vs 6%), cough (13% vs 11%), dizziness (12% vs 6%), AST increased (12% vs 7%), peripheral edema (12% vs 7%), creatinine increased (12% vs <1%), rash (11% vs 4.5%), pyrexia (11% vs 6%), and weight decreased (10% vs 2.2%).

The most frequently reported ≥5% Grade 3 or 4 adverse reactions that occurred in the Verzenio arm vs the placebo arm of MONARCH 2 were neutropenia (25% vs 1%), diarrhea (13% vs 0.4%), leukopenia (9% vs 0%), anemia (7% vs 1%), and infections (5.7% vs 3.5%).

Lab abnormalities (all grades; Grade 3 or 4) for MONARCH 2 in ≥10% for Verzenio plus fulvestrant with a difference between arms of ≥2% were increased serum creatinine (98% vs 74%; 1.2% vs 0%), decreased white blood cells (90% vs 33%; 23.7% vs .9%), decreased neutrophil count (87% vs 30%; 32.5% vs 4.2%), anemia (84% vs 34%; 2.6% vs .5%), decreased lymphocyte count (63% vs 32%; 12.2% vs 1.8%), decreased platelet count (53% vs 15%; 2.1% vs 0%), increased ALT (41% vs 32%; 4.6% vs 1.4%), and increased AST (37% vs 25%; 3.9% vs 4.2%).

The most common adverse reactions (all grades, ≥10%) observed in MONARCH 1 with Verzenio were diarrhea (90%), fatigue (65%), nausea (64%), decreased appetite (45%), abdominal pain (39%), neutropenia (37%), vomiting (35%), infections (31%), anemia (25%), thrombocytopenia (20%), headache (20%), cough (19%), constipation (17%), leukopenia (17%), arthralgia (15%), dry mouth (14%), weight decreased (14%), stomatitis (14%), creatinine increased (13%), alopecia (12%), dysgeusia (12%), pyrexia (11%), dizziness (11%), and dehydration (10%).

The most frequently reported ≥5% Grade 3 or 4 adverse reactions from MONARCH 1 with Verzenio were diarrhea (20%), neutropenia (24%), fatigue (13%), and leukopenia (5%).

Lab abnormalities (all grades; Grade 3 or 4) for MONARCH 1 with Verzenio were increased serum creatinine (99%; .8%), decreased white blood cells (91%; 28%), decreased neutrophil count (88%; 26.6%), anemia (69%; 0%), decreased lymphocyte count (42%; 13.8%), decreased platelet count (41%; 2.3%), increased ALT (31%; 3.1%), and increased AST (30%; 3.8%).

Serious and Fatal Adverse Reactions for Inluriyo in combination with Verzenio: Serious adverse reactions occurred in 21% of patients who received Inluriyo in combination with Verzenio. Serious adverse reactions in >1% of patients who received Inluriyo in combination with Verzenio included pneumonia (2.4%), abdominal pain, and renal failure (each 1.4%). Fatal adverse reactions occurred in 3.8% of patients who received Inluriyo in combination with Verzenio, including pneumonia (1.4%), myocardial infarction, interstitial lung disease, and sepsis (0.5% each).

Most Common Adverse Reactions for Inluriyo in combination with Verzenio: The most common (≥10%) adverse reactions with Inluriyo in combination with Verzenio, including laboratory abnormalities, were decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, nausea, decreased platelets, fatigue, increased triglycerides, infections, increased AST, increased creatinine, increased ALT, vomiting, musculoskeletal pain, abdominal pain, decreased appetite, increased cholesterol, rash, cough, headache, and decreased weight.

Strong and moderate CYP3A inhibitors increased the exposure of abemaciclib plus its active metabolites to a clinically meaningful extent and may lead to increased toxicity. Avoid concomitant use of ketoconazole. Ketoconazole is predicted to increase the AUC of abemaciclib by up to 16-fold. In patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the Verzenio dose to 100 mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the Verzenio dose to 50 mg twice daily with concomitant use of strong CYP3A inhibitors. If a patient taking Verzenio discontinues a strong CYP3A inhibitor, increase the Verzenio dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the inhibitor. Patients should avoid grapefruit products. With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the Verzenio dose in 50 mg decrements.

Avoid concomitant use of strong or moderate CYP3A inducers and consider alternative agents. Coadministration of strong or moderate CYP3A inducers decreased the plasma concentrations of abemaciclib plus its active metabolites and may lead to reduced activity.

With severe hepatic impairment (Child-Pugh C), reduce the Verzenio dosing frequency to once daily. No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B).

Please see full Prescribing Information and Patient Information for Verzenio.

VZ IN HCP ISI ALL APPR

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about sofetabart mipitecan as a potential treatment for ovarian cancer as well as other FRα-expressing solid tumors, olomorasib as a potential treatment for certain KRAS G12C-mutant advanced solid tumors, Retevmo (selpercatinib) as a treatment for advanced RET-mutant medullary thyroid cancer (MTC), and Verzenio (abemaciclib) as a treatment for certain HR+, HER2– breast cancers in the adjuvant and advanced or metastatic setting, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that any of these therapies will prove to be a safe and effective treatment or receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Endnotes & References

Bax, Heather J et al. "Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes." British journal of cancer vol. 128,2 (2023): 342-353. doi:10.1038/s41416-022-02031-x  Scaranti, Mariana et al. "Exploiting the folate receptor α in oncology." Nature reviews. Clinical oncology vol. 17,6 (2020): 349-359. doi:10.1038/s41571-020-0339-5.  Kalli, Kimberly R et al. "Folate receptor alpha as a tumor target in epithelial ovarian cancer." Gynecologic oncology vol. 108,3 (2008): 619-26. doi:10.1016/j.ygyno.2007.11.020.  Viricel W, et al. Cancer Res. 2023;83(suppl 7):1544.  Ji J, Wang C, Fakih M. Targeting KRAS G12C-mutated advanced colorectal cancer: Research and clinical developments. OncoTargets and Therapy. 2022;Volume 15:747-756. doi:10.2147/ott.s340392 Peng S-B, Si C, Zhang Y, et al. Abstract 1259: Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor. Cancer Research. 2021;81(13_Supplement):1259-1259. doi:10.1158/1538-7445.am2021-1259 Retevmo. Prescribing information. Lilly USA, LLC. Verzenio. Prescribing information. Lilly USA, LLC. Inluriyo. Prescribing information. Lilly USA, LLC. Refer to:  Megan Talon; [email protected] (Media)
                 Michael Czapar; [email protected] (Investors)

SOURCE Eli Lilly and Company

Three out of four crypto holders want their bank to manage their digital assets, yet most Americans still juggle separate apps, logins, and tax forms to do it. A handful of brokerages just changed that equation, but the fees, withdrawal…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A recent 2026 survey by Sentora of 10,000 U.S. crypto holders found that 75% want their banks to manage their Bitcoin (CRYPTO:BTC) and other digital currencies. The survey suggests that the large volume of crypto still stored on exchanges highlights a gap in banks’ custody options.

For many owners, managing Bitcoin has usually meant using a separate application, necessitating a different login and tax form than those used for retirement and brokerage accounts. In October, two major U.S. brokerages, Charles Schwab and Interactive Brokers, began to address this issue.

Schwab and Interactive Brokers Offer Crypto Custody, Besides Stocks

Firm
Current Offerings
Future Plans

Charles Schwab
Trading in Bitcoin and Ethereum for eligible clients
Phase in crypto deposits and withdrawals, plus add SOL, AVAX and LINK by year-end

Interactive Brokers
Crypto trading and ETH staking via Zerohash
Limited staking rollout

Deutsche Bank
No U.S. crypto offering
Plans to launch custody services in Germany first

Rick Wurster, CEO of Charles Schwab (NYSE:SCHW | SCHW Price Prediction), told analysts on October 15, “All clients can now access Schwab crypto. We are rolling out the ability for clients to transfer their crypto holdings to Schwab, and we are launching access to three new coins by the end of the year.”

These new digital currencies—Solana (CRYPTO:SOL), Avalanche (CRYPTO:AVAX) and Chainlink (CRYPTO:LINK)—will join Bitcoin and Ethereum (CRYPTO:ETH) on Schwab’s platform. This integration lets Schwab’s 48.6 million client accounts keep their crypto investments alongside their stock holdings.

Interactive Brokers (NASDAQ:IBKR) started allowing eligible clients to stake their Ether through Zerohash on October 13. Staking involves locking up coins to help secure the Ethereum network, earning rewards similar to interest on a bank deposit.

In contrast, Deutsche Bank (NYSE:DB) is launching crypto custody in Germany and currently offers no products to U.S. customers. As a result, U.S. investors primarily use brokerage accounts for crypto management rather than traditional banks.

Schwab Charges 0.75% a Trade and Caps Each Withdrawal at $5,000

Schwab charges a 0.75% fee for each crypto trade. So, for a $10,000 Bitcoin purchase, you’d pay $75 initially and about $150 total when you sell. For an investor who buys and holds for a long time, this fee might seem minimal compared to Bitcoin’s usual price fluctuations. However, for frequent traders, these fees can add up quickly.

Another consideration is the withdrawal limit: Schwab caps each crypto withdrawal at $5,000. This means that transferring $50,000 to a personal wallet would require ten separate transactions.

FDIC Insurance Doesn’t Cover Crypto, and SIPC Has Gaps

One critical concern for crypto holders is insurance. While FDIC insurance protects bank deposits, it doesn’t apply to cryptocurrencies. The SIPC provides some protection for missing assets if a brokerage firm fails, but it only covers securities and cash. Investors should carefully review their account agreements to understand how their crypto is stored. Staked assets at Interactive Brokers also fall outside SIPC protection.

In addition, staking offers potential rewards, but it also incurs costs. Interactive Brokers and Zerohash take up to 30% of the rewards earned. For example, if a client’s staked Ether yields $300 in a year, they would keep at least $210 after fees. Note that unstaking is subject to Ethereum’s waiting periods.

Near-Retirees Have Three Ways to Hold Crypto

For investors nearing retirement, there are a few ways to manage crypto:

Through Traditional Brokers: This option simplifies things, providing one login, one statement, and one tax form for year-end reporting and estate planning. However, investors may have limited coin choices and face per-trade fees and withdrawal limits, making it best for those looking to buy and hold.
Staking Ether: This can generate extra income, but it means losing SIPC protection and waiting periods if you need to access funds quickly. Staking is likely best suited for long-term Ether holders who can afford to put their investment away for a while.
Using a Crypto Exchange or Personal Wallet: This method allows for a broader selection of coins and full control. However, it puts the entire responsibility on the holder. Losing a recovery phrase might result in losing access to the coins. For many people approaching retirement, the risks of this option may outweigh the benefits of greater control.

Which U.S. Firms Already Offer Crypto Custody Beside Stocks?
Currently, Schwab and Interactive Brokers lead the way in offering crypto custody alongside traditional investments, while American investors still wait for banks to catch up.

For those near retirement who hold Bitcoin or Ethereum as a small portion of their portfolio, a brokerage they already know may offer the simplest solution—assuming they are comfortable with trading fees and understand the gaps in insurance coverage. Don’t assume familiar brands offer the same level of protection for crypto as they do for traditional assets.

Contact [email protected] for any questions or corrections.

CRISPR Therapeutics (CRSP -4.41%), a gene editing-focused biotech, has made significant clinical and regulatory progress over the past five years. However, over this period, the company has lagged broader equities. CRISPR Therapeutics' shares have declined by about 47% since mid-October 2021, while the S&P 500 has gained almost 73%, as of writing.

Will CRISPR Therapeutics continue its southbound journey through the end of the decade, or does the company have what it takes to bounce back? Let's see where the biotech might be in 2030.

Pipeline progress will be key In 2023 and early 2024, CRISPR Therapeutics earned approval for Casgevy, a gene-editing medicine for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD), both of which are blood-related disorders. CRISPR Therapeutics collaborated with Vertex Pharmaceuticals (VRTX -1.77%) to develop this therapy. The approval was an important milestone for the company for at least two reasons.

Image source: The Motley Fool.

First, before Casgevy, CRISPR Therapeutics didn't have a single product on the market. This treatment allowed it to transition to a commercial biotech. Second, Casgevy was the first CRISPR-based gene-editing therapy to earn approval. Since most of CRISPR Therapeutics' pipeline candidates are CRISPR-based gene-editing medicines, Casgevy's launch lent more credence to the company's platform. CRISPR Therapeutics hasn't made much significant clinical progress since Casgevy's approval, but the company has several exciting pipeline candidates that investors should keep an eye on.

One of them is CTX310, a medicine being developed to help lower LDL cholesterol and triglycerides (TGs) in some patients. Why is this important? At high levels, LDL and TGs can cause a range of cardiovascular problems. Treatment options do exist, but they often need to be taken daily. CTX310 could be a one-time option to help some patients reduce LDL and TGs. CRISPR Therapeutics recently reported data from a Phase 1 clinical trial in certain patients with high levels of LDL or TGs, in some cases due to rare genetic disorders. The medicine led to significant decreases in both LDL and TGs.

It's still too early to celebrate, but over the next five years, CRISPR Therapeutics could make significant progress with CTX310 and perhaps earn approval, opening up a potentially highly lucrative opportunity.

$49.25-$2.27 (-4.41%)

NASDAQ · As of 4:00 PM ET 10/16/26

CRISPR Therapeutics could also make meaningful progress with zugo-cel, an investigational medicine for several autoimmune diseases and blood cancers. Another pipeline candidate to keep an eye out for is CTX611, an investigational anticoagulant. CTX611 could be administered just twice a year, unlike today's anticoagulants, which are taken regularly. It is also being developed to reduce the risk of significant bleeding associated with many products in this niche. Perhaps the best-case scenario for CRISPR Therapeutics over the next five years would be to earn approval for all these medicines.

Hedge your bets If CRISPR Therapeutics does launch several of its promising therapies by 2030, the company's financial results will improve significantly, and its share price will likely jump. In the meantime, Casgevy's sales could also ramp up. Earlier this year, the therapy earned a label expansion in treating TDT and SCD patients as young as two, which added about 5,500 patients in the U.S. to its target market. That doesn't sound like a lot, but at a price of $2.2 million per treatment course, that's a meaningful expansion.

However, there are significant risks to consider. CRISPR Therapeutics' leading pipeline candidates could fail in clinical trials. It wouldn't be the first time the company has experienced a clinical setback. Also, many gene-editing medicines -- including some that CRISPR Therapeutics is developing -- are one-and-done treatments that are costly to manufacture and administer. So, the economics of these therapies aren't obviously conducive to profits. CRISPR Therapeutics will have to overcome this challenge.

The biotech is, without question, highly innovative, and it may see its shares soar over the medium term on strong clinical and commercial progress. But there is significant risk, too. Only investors comfortable with that should consider initiating a position in the stock.

Viking Therapeutics (VKTX -8.04%) wasted no time raising cash after the release of a successful maintenance trial, which strengthened the investment case for the stock. Viking raised more than $316 million in a stock offering at $35 per share and $258.75 million in convertible senior notes for gross proceeds of $575 million.

Why Viking Therapeutics needs the cash Clinical trials don't come cheap, and definitely not for the kind of large phase 3 trials that Viking is currently undertaking for its GLP-1 and GIP agonist, VK2735. The company is already undertaking 78-week phase 3 trials for VK2735 in subcutaneous (injectable) form in obesity (Vanquish-1) and adults with type 2 diabetes and obesity (Vanquish-2). In addition, management recently announced the initiation of 68-week phase 3 trials for VK2735 oral in obesity (Sunrise-1) and in "adults with type 2 diabetes who are obese or overweight" (Sunrise-2).

$25.17-$2.20 (-8.04%)

NASDAQ · As of 4:00 PM ET 10/16/26

In addition, Viking is currently undertaking the second part of the maintenance trial in which an initial 21-week subcutaneous dose of VK2735 will be followed by 12 weeks of a range of oral VK2735 maintenance doses.

The duration and size of these trials, as well as the company's lack of revenue, mean Viking is likely to burn cash until at least 2030, according to the Wall Street consensus from S&P Global Market Intelligence.

Clearly, Viking needs the cash not only to fund all the VK2735 trials but also to ensure the ongoing development of the rest of its pipeline, including an amylin agonist, VK3019 -- a class of weight-loss drugs that can be taken by patients who can't tolerate GLP-1 agonists or in combination with them. Eli Lilly and Novo Nordisk are also developing amylin agonists.

Image source: Getty Images.

A stock to buy? In the near future, investors are waiting for the second part of the maintenance trial. Given that it includes VK2735 oral as a maintenance dose, it's arguably much more important to the company's dual formulation strategy than the first part of the trial. Those results will hit in 2027, as will the Vanquish-1 and Vanquish-2 trials, although much later in the year, with Sunrise-1 and Sunrise-2 likely in 2028.

Given that CFO Greg Zante told investors in July that "our guidance remains intact that we have cash into 2028," the $575 million in cash will also support any commercial development of VK2735 and the company's ongoing pipeline development. In reality, the company's future pivots on the clinical success of VK2735. Still, the recent cash raise derisks the stock and enables management to continue to try to generate value for investors.

Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.

Apple keeps setting records while Bitcoin slides further from its peak, but the real question for retirement investors goes beyond recent performance. The winner of this comparison might surprise anyone who assumes crypto always wins the long game.

Apple (NASDAQ: | AAPL Price Prediction AAPL) is on a roll, consistently hitting new highs. On October 13, 2026, its stock peaked at an intraday high of $348. It crossed the $5 trillion market value threshold for the first time on October 14 and ended the trading session on October 16 with another record close at $343, marking an impressive 26.7% gain for the year.

In contrast, Bitcoin (CRYPTO:BTC) has struggled. It hit a high of $126,080 on October 6, 2025, and has not set a new high in 2026. Bitcoin trades around $81,977 as of October 18, 35% below that peak, and has declined 6.8% in 2026.

So, in the Apple vs. Bitcoin comparison, which investment is more suitable for retirement funds that investors can’t afford to lose?

Apple Excels in Income and Buybacks

Apple rewards its shareholders with returns. While its 0.31% dividend yield may seem small, the board increased the quarterly dividend by 4% to $0.27 in April and approved an additional $100 billion for share buybacks. When a company buys back its shares, fewer shares remain, so each remaining share represents a larger portion of the company’s profits.

In the June quarter alone, Apple returned $33 billion to shareholders, with $25.8 billion coming from buybacks. This distribution was made possible by a 27.1% increase in net income, totaling $29.8 billion.

On the other hand, Bitcoin is a digital currency with a capped supply and no corporate entity behind it, meaning it generates no earnings or dividends. Its price fluctuations are driven by new investments from sources like ETF buyers and corporate treasuries. Therefore, in this round, Apple comes out on top.

Bitcoin’s Volatility Can Hurt Retirees More

Over the past year, Apple has risen by 39.3%, while Bitcoin has dropped by 23.4%. Although Bitcoin rose 26.1% in the 60 days leading up to October, it remains 35% below its peak.

This price disparity can be especially detrimental for retirees relying on their investments for income. A significant decline means they would have to sell more Bitcoin to cover their expenses, locking in potential losses. With decades to wait for a recovery, younger investors may handle Bitcoin’s wild price swings better than those who are 65 or older.

Apple does carry its own risks; it trades at about 45 times earnings, which some consider steep. Additionally, management has warned of rising memory costs in the September quarter. However, Apple has beaten earnings-per-share estimates for nine consecutive quarters, giving it an edge in risk management.

Bitcoin’s Long-Term Returns Are Impressive, but Apple Is More Reliable

In terms of long-term performance, Bitcoin shines with an astonishing 12,800% gain over the past decade, compared to around 1,180% for Apple. However, this figure starts from a much lower price of approximately $631 in October 2016, when Bitcoin was still growing. Over the last five years, Bitcoin has risen by 31.6%, while Apple’s stock has surged by 143.1%.

Looking forward, Apple must maintain sales momentum, and the signs are promising. iPhone revenue rose 22% in the June quarter, and management forecasts 9% to 11% revenue growth for the September quarter. CEO Tim Cook has described the supply challenges as a “demand forecast issue,” suggesting iPhone and Mac sales have exceeded Apple’s expectations.

In contrast, Bitcoin’s success largely relies on a steady influx of new buyers, which is a less stable foundation. For this reason, Apple also looks better for the future.

Is Apple or Bitcoin a Better Investment for Retirement?
In the Apple vs. Bitcoin debate, Apple is the healthier choice for retirement. It provides steady earnings, a growing dividend, and consistent buybacks, while Bitcoin has fallen 35% from its peak. Bitcoin may appeal more to younger investors who can take a small, speculative position and wait years for a recovery. However, retirees choosing Bitcoin face significant price fluctuations that could force them to sell at a loss.

Apple’s next test will be its pricing strategy, particularly with its new $1,999 iPhone Duo, which may reveal whether consumers are willing to continue paying a premium for the brand. Our perspective could shift if Apple’s next earnings report misses its 9% to 11% revenue guidance while Bitcoin breaks back above its $126,080 record, a 54% climb from its current price.

Contact [email protected] for any questions or corrections.

Hedge funds have long kept systematic long/short strategies out of reach for ordinary investors, but WisdomTree just listed two ETFs on the Texas Stock Exchange that aim to change that using AI models from a firm WisdomTree now partly owns.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

On October 8, 2026, WisdomTree announced the launch of the WisdomTree Efficient Long/Short U.S. SmallCap Equity Fund (TXSE:WSLS) and the WisdomTree Global Alpha Fund (TXSE:WTAL). Both funds have an expense ratio of 0.88%.

WisdomTree says the two funds give investors access to systematic long/short strategies “traditionally associated with hedge funds” through an ETF structure. They are WisdomTree’s first launches on the Texas Stock Exchange (TXSE), which already lists ETFs from other issuers.

How a Long/Short Fund Tries to Make Money
A long position makes money when a stock rises. A short position makes money when a stock falls. A fund that holds both can try to earn from the gap between the stocks it expects to do well and the ones it expects to lag.

A long/short strategy can seek returns from relative stock performance, but its sensitivity to the overall market depends on how the long and short exposures are balanced. WSLS also retains broad small-cap market exposure.

WisdomTree has used this approach before. The new funds build on the WisdomTree Efficient Long/Short U.S. Equity Fund (WTLS), which WisdomTree launched in January 2026.

WSLS Stacks a Stock-Picking Layer on Top of Small Caps
WSLS holds broad U.S. small-cap exposure, either through stocks or through derivatives (contracts whose value tracks an underlying asset), and on top of that core it runs a dynamic long/short “overlay,” which is a second strategy layered over the main holdings. WisdomTree’s thinking is that individual small-cap stocks have more widely spread returns, which may give its models more room to add value.

WTAL Aims to Earn Whether Markets Rise or Fall
WisdomTree says WTAL runs two long/short overlays: one in U.S. stocks and one in international stocks. According to WisdomTree, it gets that exposure through derivatives, including swaps (agreements in which two parties trade the returns of different assets), and holds Treasuries and cash as collateral.

WisdomTree says WTAL aims for a market-neutral return stream, meaning its results should come from how its stock picks perform against each other, with market direction playing a much smaller role. A traditional stock fund earns money when markets rise. WTAL is designed to earn from the spread between its winners and losers in any kind of market.

According to Jeremy Schwartz, WisdomTree’s Global Chief Investment Officer, “many investors want returns that don’t simply rise and fall with the broader market, but accessing those returns has often meant adding complexity to a portfolio.”

An Israeli Fintech Partner WisdomTree Partly Owns
Both funds pick investments using machine learning models developed by AlphaBeta. The models are trained on historical data to forecast a security’s return and/or risk. AlphaBeta is an Israeli fintech firm that specializes in quantitative and AI-driven strategies, and WisdomTree announced a strategic minority investment in the company in November 2025.

Leverage, Models and a Fee Hurdle
WisdomTree’s own disclosures list the risks. Both funds use derivatives, which create leverage, and the value of an investment may change quickly and without warning. Both are actively managed but rely heavily on quantitative models that may not perform as intended. WTAL also carries the added risks of investing in foreign stocks.

At WisdomTree’s stated 0.88% a year, each fund has to earn back its fee before an investor gets any benefit. That fee is far higher than many plain index funds charge, so the models have to produce enough extra return to cover the difference.

What to Look For Going Forward
Putting hedge fund-style strategies inside an ETF fixes the access problem. Anyone with a brokerage account can buy shares, with no high minimum investment. The harder question is whether the models can produce returns that support the fee and the leverage.

Over the coming months, investors can monitor asset growth, holdings, trading spreads, and shareholder reports, while assessing whether the strategies deliver adequate returns after expenses. For more on recent ETF launches on the same exchange, see our coverage of a new power-focused ETF that also sells calls.

Contact [email protected] for any questions or corrections.

NEW YORK, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Duolingo, Inc. (NASDAQ: DUOL) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Duolingo securities between May 2, 2025 and February 26, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/duolingo-inc-duol-class_action_lawsuit.

Duolingo Case Details

The Complaint alleges that throughout the Class Period, Defendants failed to disclose that:
(1)   Daily Active User (“DAU”) growth rates were being leveraged against deliberately added user friction in the form of significant increases in ad volume, subscription tier upsells, and worsened product quality, and Duolingo understood that any amount of user friction would cause users to leave the app and, ultimately, negatively impact DAU growth rates;
(2)    the Company’s rigorous A/B testing demonstrated that increased friction in the free user experience was having negative impacts on DAU growth rates;
(3)   Duolingo’s quickly generated AI content was worsening the quality of the Company’s product offerings, negatively impacting the user experience and user trends, and threatening the sustainability of the Company’s financial performance; and
(4)   Duolingo’s constant A/B testing informed the Company that its monetization push and lower-quality, rapidly generated AI content were degrading the Duolingo product experience and the value proposition of its subscription tiers.

What's Next for Duolingo Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/duolingo-inc-duol-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Duolingo you have until December 7, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Duolingo Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Duolingo Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

Fresh off a $2 billion re-fi, SL Green’s 1.8 million square-foot 245 Park Avenue reached 100% occupancy in September — and that’s only part of the property’s story.

The 44-story tower on the entire block between East 46th and East 47th is putting the finishing touches on what SL Green CEO Marc Holliday called a “seismic,” $225 million repositioning. The project includes a new wraparound public plaza, a striking new Park Avenue podium facade by KPF, lavish tenant amenities and, soon, a restaurant from John Meadow’s LDV Hospitality.

A rendering of 245 Park Ave. after its $225 million facelift is complete. SL Green
“It’s a quintessential SLG Green case study,” Holliday told us. “It was a comprehensive re-do from the plaza to the roof. We breathe new life into older buildings and bring them up to world-class standards.” The work is expected to wrap up in March.

Holliday credited joint-venture partner Mori Trust and architects KPF for “sharing our vision” to make 245 Park Avenue fully competitive in the red-hot Park Avenue market. He also expressed gratitude to the Department of City Planning for cooperating in the plaza redesign.

Rents at 245 Park were around $85 per square foot when SL Green took total control of the property in 2022 following a “contentious bankruptcy” by the previous owner, Holliday said. More recent “asks” were as high as $185 psf. The lease that filled the building was for Nearwater Management, which took 36,563 square feet.

SL Green CEO Marc Holliday said 245 Park’s rents were $85 per square foot when the company took over the property in 2022. Recent “asks” were up to $185 psf.
SL Green first entered the 245 Park picture as a lender in 2018. It was technically about 80% full when SL Green took over four years later, but that’s misleading since a number of leases were expiring. “We had to re-establish good tenant relationships” after disruption during the bankruptcy, Holliday said. The tower has since lured Area Management, Carlyle Investment Management, EQT Partners and Houlihan Lokey.

245 Park Ave.’s facelift includes lavish tenant amenities. SL Green
Holliday said of the re-fi, “We’re thrilled at the support we got from the debt community, it’s very satisfying.” The new loan led by JP Morgan Chase and including six other banks replaced a $1.2 billion mortgage loan and a $568 mezzanine loan.

The tower will soon have a  restaurant from John Meadow’s LVD Hospitality. It will fill a 10,000 square-foot ground-level corner at the north end of the Park Avenue side.

“The space was vacant for many years. We don’t know why,” Holliday said. “We chose LVD because they’re great operators.” Meadow is known for his popular Scarpetta trattorias but a concept for 245 Park has yet to be chosen.

Gilead Sciences (GILD -0.75%), a biotech leader, has outperformed broader equities this year. The company's financial results have been fairly strong, contributing to its year-to-date performance. However, another factor behind Gilead Sciences' run is its important regulatory progress, which has improved its lineup of approved drugs. That's all well and good, but after climbing by almost 30% this year, are Gilead's shares still attractive?

Recent approvals could move the needle Over the past few years, Gilead Sciences has experienced declining sales from its coronavirus medicine, Veklury. The company's financial results have sometimes been mixed as a result, but things are trending up for the biotech giant. In the second quarter, Gilead Sciences' revenue came in at $7.8 billion, up 10% year over year. Product sales excluding Veklury also grew by 10% compared to the year-ago period. The company reported a non-GAAP loss per share of $6.75, compared to earnings per share of $2.01 in the year-ago period. The decline was mostly due to acquisition-related expenses.

Image source: Getty Images.

Gilead Sciences' core HIV portfolio was the primary driver of this performance. HIV product sales came in at $5.7 billion, up 12% year over year. The good news is that recent approvals (and label expansions) will help strengthen the company's HIV lineup and diversify its portfolio. In late August, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) had approved Bixlenvo, an HIV regimen. Bixlenvo is a daily oral tablet that combines two existing HIV medicines.

It helps simplify treatment for certain patients who were taking more than one pill per day. According to some estimates, that represents 5% of HIV patients in the U.S. That's in the neighborhood of 58,000 people. So, this market isn't huge. But the approval of Bixlenvo helps solidify Gilead Sciences' leadership position in the HIV market. Moving beyond HIV, Gilead Sciences received a label expansion for Trodelvy, a cancer medicine, in June. Trodelvy can now be used as a first-line treatment in metastatic triple-negative breast cancer.

The medicine was already indicated for previously treated breast cancer, but the first-line indication tends to be the most lucrative. That's because drugs approved as second- or third-line treatments are eligible for only a fraction of the patient pool, whereas being indicated as a first-line treatment means eligibility for all newly diagnosed patients. That's why the recent Trodelvy label expansion in one of the deadliest cancers in the world could be particularly important.

$156.19-$1.18 (-0.75%)

NASDAQ · As of 4:00 PM ET 10/16/26

Lastly, in May, Gilead Sciences earned approval for Hepcludex, a medication for chronic hepatitis delta virus (HDV) infection. It will be a nice addition to the company's liver disease portfolio, which is performing fairly well. Second-quarter liver disease sales came in at $877 million, up 10% year over year. Management expects Hepcludex to be a modest growth contributor in this segment.

A reliable dividend stock Gilead Sciences' brand-new approvals -- and the Trodelvy label expansion -- should help the company's revenue and earnings move in the right direction over the medium term as the impact of Veklury on its financial results fades. Of course, the biotech giant can still count on several of its flagship products. None is more important than Biktarvy, an HIV medicine. Biktarvy is the leading HIV treatment in the U.S. Descovy for PrEP is another important growth driver.

Gilead Sciences should also make significant clinical and regulatory progress over the next few years, especially in HIV and oncology. So, the company's financial results should remain strong in the medium term. Here's another good reason to consider Gilead Sciences: It is a solid dividend stock. The company boasts a forward yield of 2.2%, compared with the S&P 500's average of 1.1%, and has increased its payouts by 74.5% over the past decade. Gilead Sciences appears to be an attractive dividend payer for long-term investors.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of J.B. Hunt Transport Services, Inc. (NASDAQ: JBHT) resulting from allegations that J.B. Hunt may have issued materially misleading business information to the investing public.

So What: If you purchased J.B. Hunt securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/jb-hunt-transport-services-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On September 16, 2026, CNBC published an article entitled "J.B. Hunt stock plunges 10% after company warns third-quarter earnings will fall." The article further stated that J.B. Hunt's Chief Financial Officer had "said between costs for recruiting, advertising, onboarding, training and sign-on bonuses, the company expects to see about $25 million more in the third quarter compared with the second quarter."

On this news, J.B. Hunt's shares fell sharply in intraday trading on September 16, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

New York, New York--(Newsfile Corp. - October 18, 2026) - Lead Plaintiff Deadline: December 15, 2026. Investors who purchased (NASDAQ: QBTS) securities between February 26, 2026 and August 25, 2026 may be eligible to recover losses.

Bronstein, Gewirtz & Grossman, LLC ("BG&G"), a nationally recognized investor-rights law firm, announces that it has filed a securities class action lawsuit against D-Wave Quantum Inc. (NASDAQ: QBTS) ("D-Wave" or the "Company") and certain of its officers.

The lawsuit, captioned, Case No. 5:26-cv-11953, was filed on October 15, 2026, in the United States District Court for the Northern District of California. The action seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired D-Wave securities between February 26, 2026 and August 25, 2026, both dates inclusive (the "Class Period"), for alleged violations of the federal securities laws.

Investors are encouraged to join this case by visiting the firm's website: https://bgandg.com/cases/d-wave-quantum-inc-qbts-class_action_lawsuit/

D-Wave Case Details

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and financial prospects. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:

Defendants materially overstated D-Wave's business, operational, and financial prospects; The foregoing was reasonably likely to negatively impact the Company's business and reputation; and As a result, Defendants' public statements were materially false and misleading at all relevant times.On August 6, 2026, D-Wave reported second-quarter revenue of $3.08 million, falling short of analysts' expectations of approximately $4.03 million to $4.08 million. On this news, D-Wave's stock price declined $1.99 per share, or 9.28%, closing at $19.41 per share.

Then, on August 25, 2026, D-Wave announced that Chief Financial Officer John Markovich would retire and resign from his position effective September 2, 2026. On this news, D-Wave's stock price fell $1.84 per share, or 9.51%, closing at $17.51 per share on August 26, 2026.

What's Next for D-Wave Investors?

Bronstein, Gewirtz & Grossman, LLC has already filed a class action lawsuit on behalf of D-Wave investors. The action is pending in the United States District Court for the Northern District of California under Case No. 5:26-cv-11953.

If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/cases/d-wave-quantum-inc-qbts-class_action_lawsuit, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in D-Wave you have until December 15, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to D-Wave Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for D-Wave Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising.
Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319389

Source: Bronstein, Gewirtz & Grossman, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Magnificent Seven company Meta Platforms NASDAQ: META recently made a landmark statement related to its artificial intelligence journey.

Meta Platforms Today

$709.33 -27.39 (-3.72%)

As of 10/16/2026 04:00 PM Eastern

$520.26▼

$779.820.30%

26.72

$808.88

The company claims that Muse Wonder, its latest model family, is frontier-class, putting it in the same territory as models developed by OpenAI and Anthropic.

Get Meta Platforms alerts:

This marks the first time Meta has framed its Muse models as among the most intelligent available. And, investors don’t just have to take Meta’s word for it; model evaluation sites provide third-party validation of this claim.

As Meta looks to improve AI monetization over time, developing a leading-class model could be a key benefit the firm has historically lacked.

Meta’s New Muse Models Move Up in Frontier Ranking HierarchyApproximately 14 months ago, Meta began to “overhaul” its AI efforts. This overhaul included launching Meta Superintelligence Labs (MSL) and hiring Alexandr Wang to lead the division. Before this, investors saw Meta’s Llama models as lagging far behind the frontier, leaving them with limited confidence in the company’s ability to compete with other LLM developers.

By April 2026, MSL released its first model, Muse Spark. Although the firm noted that Muse Spark was its most powerful model yet, the company framed it as being “competitive” rather than pushing the frontier of model development. With the release of Muse Wonder and Muse Wonder Full, that framing has changed.

Meta now notes that the Muse Wonder models “deliver state-of-the-art performance on personal and professional agentic tasks.” Data from the model evaluation site, Artificial Analysis, supports Meta’s assessment and highlights a significant jump in performance compared to its previous model, Muse Spark 1.3.

On its Artificial Analysis Intelligence Index, the evaluator gives Muse Wonder Full a score of 56. This ties for the second-highest score of any model, with Anthropic’s Claude Sonnet 5.5 also scoring 56. Anthropic’s Claude Opus 5.5 has the highest score at 58. Muse Wonder Full notably ranks above OpenAI’s GPT-6 Astra and Alphabet’s NASDAQ: GOOGL Gemini 4 Argon, which both have scores of 53. Meanwhile, Muse Wonder scores slightly lower at 52.

With Muse Wonder Full and Muse Wonder both ranking in this upper echelon, Artificial Analysis’s data supports the idea that Meta now has frontier-class models in its hands. The firm also notes a significant jump in the capabilities of these models compared to Muse Spark 1.3, which has a score of 48.

Meta Raises Model Prices, Keeps Muse Wonder Full Behind Subscription WallInterestingly, Muse Wonder comes with a hefty price increase versus Muse Spark 1.3. On their max settings, Muse Wonder’s cost per Artificial Analysis Intelligence Index task is $4.52, or 2.8 times higher than Muse Spark 1.3’s cost of $1.60. This is still meaningfully below the cost per task of Anthropic’s most intelligent models, but also significantly higher than OpenAI and Alphabet’s top models. The increase suggests that Meta believes the model’s improved capabilities justify a higher price.

On the other hand, the more powerful Muse Wonder Full is only available through $50 per month and $200 per month subscriptions to Muse Code, not on a per-token basis. This suggests that Meta primarily wants to position Muse Wonder Full as being for agentic coding tasks, while Muse Wonder is more for general-purpose usage. It also suggests that Meta hopes to build a more stable, subscription-based revenue stream by keeping Muse Wonder Full behind this gate.

Additionally, by keeping Muse Wonder Full access to only Muse Code subscribers, it gives software developers a reason to try Muse Code. This could help Meta position Muse Code as a competitor to Anthropic’s Claude Code and OpenAI’s Codex. Still, only time will tell whether software developers actually stick with Muse Code rather than experimenting with it for a short time.

Meta notes that Muse Wonder will soon power more of its Muse agent. As the company looks to scale this product, Muse Wonder’s improved capabilities could improve user experiences and aid demand.

Meta Releases a Flurry of Products With Q3 Earnings on the HorizonMeta has demonstrated the ability to significantly improve its models in a relatively short time. This bodes well for the company’s ability to continue competing with other model developers on frontier intelligence and to scale its non-advertising AI revenue. However, up to this point, Meta’s non-ad AI potential has yet to meaningfully translate into its financial results.

The Muse agent, the Meta Enterprise Platform, Muse Code, and now the Muse Wonder model releases should make Meta’s future earnings calls more interesting. Investors should look for signs of strong early adoption and, over time, a contribution to revenue growth. Meta’s next earnings report is quickly approaching, slated for Oct. 21 after the market close.

Should You Invest $1,000 in Meta Platforms Right Now?Before you consider Meta Platforms, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Meta Platforms wasn't on the list.

While Meta Platforms currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

In Brief

Posted:

Image Credits:Character.AI

After chatbot startup Character.AI filed for bankruptcy earlier this week, many of its employees will have the opportunity to take jobs at Disney.

Character.AI’s former CEO Karandeep Anand recently became the entertainment giant’s first CTO, and the startup previously said that Disney had agreed to acquire some of its assets for $20 million.

A legal filing spotted by Bloomberg revealed more details about the agreement between Character.AI and Disney, with Disney agreeing to make employment offers to at least 60 Character.AI employees — the majority of the workforce — paying them an estimated $60 million in annual compensation.

The filing also says that the “vast majority” of Character.AI employees who were offered jobs at Disney accepted them. However, this is a stalking horse bid, so another company could come forward with a higher offer.

The filing says that despite its “large and engaged user base,” Character.AI has been hobbled by high costs and “potential litigation-related liabilities and regulatory engagement.” (The company was sued by the mother of a 14-year-old boy who said her son became obsessed with one of Character.AI’s chatbots before committing suicide; it also faces government investigations over child safety concerns.)

Topics

Subscribe for the industry’s biggest tech news

Latest in AI

Warren Buffett’s bet on Occidental Petroleum (NYSE: OXY) is seemingly paying off, with the stock rising over 50% in the past year. 

Notably, OXY shares reached a 52-week high of $67.45 on March 31 before retreating and recovering, settling at $62 as of press time, up 52% over the past year. 

OXY one-year stock price chart. Source: Google Finance Occidental’s recovery reflects improving fundamentals and higher oil prices amid US-Iran tensions and concerns about disruptions to crude shipments through the Strait of Hormuz. Its average realized crude oil price rose 32.6% year over year in the third quarter.

Berkshire’s Hathaway’s (NYSE: BRK.A, BRK.B) investment gives it exposure to Occidental’s production assets and cash flows. 

Berkshire stake in Occidental The relationship also deepened when Berkshire completed its $9.7 billion cash acquisition of Occidental’s OxyChem business on January 2, 2026, giving the oil producer greater flexibility to reduce debt and focus on its core operations.

At the same time, Berkshire’s first-quarter filing showed a 26.9% stake, excluding the potential effect of outstanding warrants. 

Occidental’s 2025 annual filing separately listed Buffett and affiliated entities as holding 348.9 million shares and warrants, equivalent to 32.43% of outstanding common stock under that disclosure’s methodology.

Meanwhile, Occidental’s second-quarter 2026 results reported net income of $2.8 billion, or $2.75 per diluted share, and adjusted earnings of $2.40 per share. Operating cash flow reached $5.1 billion, while free cash flow before working capital hit $3 billion, its highest level since Q3 2022.

Production averaged 1.433 million barrels of oil equivalent per day, exceeding the high end of guidance. Occidental also reduced principal debt by $1.9 billion to $11.8 billion, moving closer to its $10 billion target.

Further debt reduction could lower interest expenses and free up cash for dividends, share repurchases and production investments.

OXY third quater outlook Third-quarter pricing data reinforced the favorable operating environment. Occidental’s average realized crude oil price rose 32.6% year over year to $85.91 per barrel, while Brent averaged $89.27, up 31.2%. Realized natural gas liquids prices increased nearly 26% to $24.63 per barrel.

However, production at some Gulf of America facilities was temporarily curtailed in September because of a third-party gas pipeline constraint and maintenance. 

Production was partially restored, with the remaining affected output expected to return as the issue was resolved.

Oil-price volatility remains the main risk. In this case, easing geopolitical tensions, weaker demand, increased competing supply, or changes in OPEC+ output could pressure crude prices and Occidental’s margins. 

Other risks include debt obligations, production costs, exploration uncertainty, environmental regulations and operational disruptions.

OXY investment case  Overall, after its 52% rally, Occidental is no longer an obvious bargain. Its investment case depends on sustained cash generation, disciplined spending and further debt reduction. 

Berkshire’s substantial stake supports investor interest but does not guarantee future returns, particularly given its longer investment horizon.

On its third quarter of 2026 earnings call, held on Oct. 14, 2026, State Street (STT -1.12%) reported a 33% year-over-year increase in per-share earnings to $3.69 and 13% year-over-year growth in total revenue to $4 billion. Fee-based revenue and interest margin expansion demonstrate that scale and pricing power are driving operating efficiency. Three key takeaways from management's comments highlight the long-term outlook.

1. Wealth Management Services Gain Traction With Large Registered Investment AdvisorsState Street expanded its reach into servicing registered investment advisors (RIAs), or independent wealth management firms, by pairing its front-office software with custody services. Winning large advisor mandates validates its strategy to capture growing individual investor asset pools.

During the third quarter, we secured a servicing mandate from one of the largest RIAs in the United States, an important validation of both the market opportunity and our value proposition.
-- Ronald O'Hanley, Chairman and Chief Executive Officer2. Alternative Asset Servicing Expands Across Complex Private MarketsDemand for private credit and alternative asset administration continues to accelerate as institutional portfolios diversify. The company uses specialized software and administrative capabilities to capture higher-margin private market servicing fees.

Alternative servicing fees grew at a double-digit rate year-over-year in the third quarter, reflecting solid growth across private markets and strong client activity.
-- Ronald O'Hanley, Chairman and Chief Executive Officer3. Net Interest Margin Expansion Drives Operating LeverageHigher yields on interest-earning assets expanded net interest income, or the spread earned between interest assets and funding liabilities. Combined with disciplined productivity controls, higher interest income allowed revenue growth to outpace expense growth, thereby strengthening operating leverage.

Net interest income of $864 million increased 21% year-over-year in the third quarter, driven primarily by continued net interest margin expansion and supported by growth in the average interest-earning assets as well.
-- John Woods, Chief Financial OfficerLooking AheadRevenue momentum is accelerating across custody, market services, and asset management, and management isn't hiding its satisfaction about full-year operating leverage. Massive global scale, integrated software platforms, and sticky client relationships position the business to capture higher fee revenue over time. Executive focus remains on pricing discipline, deposit retention, and technology execution.

Taken together, we expect to deliver over 500 basis points of positive operating leverage in 2026.
-- John Woods, Chief Financial OfficerWith assets under custody and administration reaching a record $59.2 trillion and digital initiatives advancing, the strategic foundation supports long-term value creation.

Quarter after quarter, our results continue to validate that our strategy is working and delivering consistent, durable improvement in financial performance.
-- Ronald O'Hanley, Chairman and Chief Executive OfficerThe Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Cooper Companies, Inc. (NASDAQ: COO) resulting from allegations that Cooper Companies may have issued materially misleading business information to the investing public.

So What: If you purchased Cooper Companies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/the-cooper-companies-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On September 10, 2026, The Motley Fool published an article entitled "Why is Cooper Companies Stock Down 15% Today?". The article stated that Cooper Companies stock fell "after the company's earnings report disappointed Wall Street with weak guidance and a decision to not sell CooperSurgical."

On this news, Cooper Companies's stock fell 14.6% on September 10, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Reddit Inc. (NYSE:RDDT – Get Free Report) CEO Steve Huffman sold 17,308 shares of the firm’s stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $158.57, for a total value of $2,744,529.56. Following the completion of the sale, the chief executive officer owned 336,432 shares in the company, valued at $53,348,022.24. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steve Ladd Huffman also recently made the following trade(s):

On Tuesday, September 29th, Steve Huffman sold 17,308 shares of Reddit stock. The shares were sold at an average price of $144.87, for a total transaction of $2,507,409.96. On Tuesday, September 15th, Steve Huffman sold 17,308 shares of Reddit stock. The shares were sold at an average price of $160.11, for a total transaction of $2,771,183.88. On Monday, August 31st, Steve Huffman sold 18,000 shares of Reddit stock. The shares were sold at an average price of $148.02, for a total transaction of $2,664,360.00. On Friday, August 14th, Steve Huffman sold 18,000 shares of Reddit stock. The shares were sold at an average price of $178.16, for a total transaction of $3,206,880.00. On Tuesday, August 4th, Steve Huffman sold 18,000 shares of Reddit stock. The shares were sold at an average price of $159.78, for a total transaction of $2,876,040.00. Reddit Trading Down 2.1% NYSE RDDT opened at $155.97 on Friday. Reddit Inc. has a 52 week low of $119.27 and a 52 week high of $263.50. The stock has a market cap of $30.01 billion, a price-to-earnings ratio of 36.27, a price-to-earnings-growth ratio of 0.72 and a beta of 2.05. The company has a 50-day moving average price of $154.22 and a two-hundred day moving average price of $161.39.

Reddit (NYSE:RDDT – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $0.95 by $0.30. The company had revenue of $804.91 million for the quarter, compared to analyst estimates of $731.00 million. Reddit had a net margin of 31.35% and a return on equity of 29.02%. Reddit’s revenue was up 61.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.45 earnings per share. As a group, equities research analysts expect that Reddit Inc. will post 5.27 earnings per share for the current fiscal year. Hedge Funds Weigh In On Reddit Several large investors have recently bought and sold shares of the stock. State Street Corp raised its position in shares of Reddit by 8.7% during the 2nd quarter. State Street Corp now owns 2,979,587 shares of the company’s stock worth $517,197,000 after buying an additional 237,523 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Reddit by 21.8% in the 2nd quarter. Wellington Management Group LLP now owns 1,564,535 shares of the company’s stock worth $271,572,000 after acquiring an additional 280,030 shares during the period. DSM Capital Partners LLC boosted its holdings in shares of Reddit by 5.3% in the first quarter. DSM Capital Partners LLC now owns 848,206 shares of the company’s stock valued at $114,211,000 after acquiring an additional 42,808 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Reddit by 8.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 481,893 shares of the company’s stock valued at $83,647,000 after acquiring an additional 39,540 shares in the last quarter. Finally, Bessemer Group Inc. boosted its holdings in shares of Reddit by 2.4% in the first quarter. Bessemer Group Inc. now owns 469,907 shares of the company’s stock valued at $63,273,000 after acquiring an additional 10,996 shares in the last quarter.

More Reddit News Here are the key news stories impacting Reddit this week:

Positive Sentiment: CNBC’s Jim Cramer recommended buying Reddit, describing the shares as “inexpensive.” The endorsement could improve retail-investor sentiment and draw attention to Reddit’s valuation. Jim Cramer recommends Reddit Neutral Sentiment: Reddit will report third-quarter results on Thursday, October 29. Investors are likely to focus on advertising growth, user trends and management’s outlook following the company’s previous quarterly revenue increase of 61% year over year. Reddit third-quarter earnings announcement Neutral Sentiment: Goldman Sachs maintained its Hold rating on RDDT, indicating that the firm does not see a sufficiently compelling risk-reward profile at current levels. Goldman Sachs maintains Hold rating Negative Sentiment: CEO Steve Huffman sold 17,308 shares for approximately $2.74 million, reducing his direct holdings by 4.89%. COO Jennifer Wong separately sold 60,000 shares for about $9.03 million, reducing her position by 5.60%. Both transactions were made under pre-arranged Rule 10b5-1 plans, which lessens—but does not eliminate—the negative signaling effect of insider selling. Reddit insider sales Analyst Ratings Changes A number of equities analysts recently issued reports on RDDT shares. Roth Capital reissued a “neutral” rating and issued a $145.00 price objective on shares of Reddit in a report on Monday, August 3rd. Wells Fargo & Company lowered their target price on Reddit from $187.00 to $142.00 and set an “equal weight” rating on the stock in a research report on Friday, July 31st. Guggenheim reaffirmed a “buy” rating on shares of Reddit in a research note on Wednesday, September 16th. Sanford C. Bernstein reiterated a “market perform” rating and set a $180.00 price target on shares of Reddit in a research report on Friday, July 31st. Finally, Wedbush reduced their price target on Reddit from $250.00 to $221.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $219.29.

Check Out Our Latest Report on Reddit

Reddit Company Profile (Get Free Report)

Reddit, Inc operates a global online platform where users participate in communities organized around shared interests, topics and experiences. Registered users can submit posts, images, videos and links, while other users can comment, vote on content and engage in discussions. The platform comprises thousands of independently moderated communities, commonly known as subreddits.

Reddit generates revenue primarily through digital advertising and other commercial offerings for businesses.

Read More Five stocks we like better than Reddit Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery

Receive News & Ratings for Reddit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reddit and related companies with MarketBeat.com's FREE daily email newsletter.

Counterpoint Mutual Funds LLC purchased a new stake in Sandisk Corporation (NASDAQ:SNDK – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 5,897 shares of the data storage provider’s stock, valued at approximately $10,260,000. Sandisk accounts for approximately 0.9% of Counterpoint Mutual Funds LLC’s holdings, making the stock its 16th largest position.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dogwood Wealth Management LLC lifted its holdings in Sandisk by 14.3% in the second quarter. Dogwood Wealth Management LLC now owns 48 shares of the data storage provider’s stock valued at $109,000 after acquiring an additional 6 shares during the last quarter. Nilsine Partners LLC grew its position in Sandisk by 3.2% in the second quarter. Nilsine Partners LLC now owns 226 shares of the data storage provider’s stock worth $514,000 after acquiring an additional 7 shares during the period. Insight Wealth Partners LLC grew its position in Sandisk by 0.4% in the second quarter. Insight Wealth Partners LLC now owns 1,607 shares of the data storage provider’s stock worth $3,654,000 after acquiring an additional 7 shares during the period. Cornerstone Financial Management LLC grew its position in Sandisk by 60.0% in the second quarter. Cornerstone Financial Management LLC now owns 24 shares of the data storage provider’s stock worth $55,000 after acquiring an additional 9 shares during the period. Finally, LifeGoal Investments LLC increased its stake in Sandisk by 3.9% during the third quarter. LifeGoal Investments LLC now owns 242 shares of the data storage provider’s stock worth $421,000 after acquiring an additional 9 shares during the last quarter.

Sandisk Stock Performance NASDAQ:SNDK opened at $1,299.30 on Friday. The stock has a market capitalization of $187.79 billion, a P/E ratio of 17.82, a PEG ratio of 0.13 and a beta of 5.23. The company has a 50 day moving average price of $1,603.61 and a 200 day moving average price of $1,496.95. Sandisk Corporation has a fifty-two week low of $136.29 and a fifty-two week high of $2,354.39.

Sandisk (NASDAQ:SNDK – Get Free Report) last announced its earnings results on Wednesday, August 5th. The data storage provider reported $39.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $33.28 by $5.97. Sandisk had a return on equity of 87.84% and a net margin of 56.47%. The company had revenue of $8.96 billion for the quarter. During the same period in the previous year, the firm earned $0.29 EPS. The firm’s revenue for the quarter was up 371.6% compared to the same quarter last year. Sandisk has set its Q1 2027 guidance at 44.000-46.000 EPS. Research analysts forecast that Sandisk Corporation will post 208.94 earnings per share for the current fiscal year. Sandisk announced that its Board of Directors has initiated a share buyback program on Wednesday, August 5th that allows the company to buy back $14.00 billion in shares. This buyback authorization allows the data storage provider to repurchase up to 6.6% of its shares through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes SNDK has been the topic of a number of research analyst reports. UBS Group restated an “overweight” rating and issued a $1,750.00 target price on shares of Sandisk in a research report on Friday, August 14th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $1,400.00 price target (up from $1,000.00) on shares of Sandisk in a research note on Thursday, August 6th. Rosenblatt Securities assumed coverage on Sandisk in a report on Tuesday, September 22nd. They set a “buy” rating and a $2,400.00 price target for the company. Sanford C. Bernstein reiterated an “outperform” rating and set a $3,000.00 price target (up from $1,700.00) on shares of Sandisk in a report on Thursday, August 6th. Finally, Bank of America boosted their price objective on shares of Sandisk from $2,100.00 to $2,500.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $2,120.65.

Check Out Our Latest Stock Analysis on SNDK

Key Stories Impacting Sandisk Here are the key news stories impacting Sandisk this week:

Positive Sentiment: Sandisk’s long-term growth case remains supported by strong data-center demand. One analysis argues that the company’s revenue growth, earnings power and $15.5 billion buyback authorization could support further earnings-per-share accretion if cash generation remains robust. Sandisk: The Earnings Boom Is Only Half The Story Positive Sentiment: Sandisk reportedly has at least $93.9 billion of expected revenue secured through multiyear contracts, including financial protections if customers fail to meet commitments. This provides meaningful demand visibility despite near-term market volatility. SanDisk Stock Is Falling on AI Fears. Its $93.9 Billion Contract Book Tells Another Story Positive Sentiment: Bullish analysts say continued AI infrastructure spending and data-center demand could drive substantial additional upside, with one projection placing the shares at $4,128 over the next year. Sandisk Stock Could Be Worth $4,128 in the Next Year Neutral Sentiment: Sandisk was upgraded by Zacks Research from “hold” to “strong buy,” although the upgrade has not offset broader sector selling. Negative Sentiment: Memory-chip stocks, including Sandisk, Micron and SK Hynix, are continuing a multiday selloff. Investors are concerned about Chinese competitors’ server-memory plans, cyclical oversupply and the durability of recent margin expansion. Memory Stocks Extend Selloff on China Competition Fears Negative Sentiment: Cathie Wood warned that memory-chip cycles can be “vicious” and indicated that her ARK strategy is moving away from the group, raising concerns that Sandisk’s rapid gains and expanding margins may not be sustainable. Cathie Wood Says the Memory Chip Trend Is Up but the Cycles Are Vicious Negative Sentiment: Higher Treasury yields and the possibility of an October Federal Reserve rate hike are weighing on growth and AI-related equities, adding to pressure on Sandisk. Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink Insider Transactions at Sandisk In other news, CFO Luis Visoso sold 1,000 shares of Sandisk stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $1,568.83, for a total value of $1,568,830.00. Following the completion of the sale, the chief financial officer directly owned 130,976 shares of the company’s stock, valued at approximately $205,479,078.08. The trade was a 0.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO David Goeckeler sold 33,841 shares of Sandisk stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $1,574.21, for a total value of $53,272,840.61. Following the completion of the sale, the chief executive officer directly owned 382,865 shares of the company’s stock, valued at $602,709,911.65. The trade was a 8.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 77,899 shares of company stock valued at $121,159,122. Corporate insiders own 0.29% of the company’s stock.

Sandisk Company Profile (Free Report)

SanDisk Corporation offers flash storage solutions. The Company designs, develops and manufactures data storage solutions in a range of form factors using flash memory, controller, firmware and software technologies. The Company operates through flash memory storage products segment. Its solutions include a range of solid state drives (SSD), embedded products, removable cards, universal serial bus (USB), drives, wireless media drives, digital media players, and wafers and components. It offers SSDs for client computing applications, which encompass desktop computers, notebook computers, tablets and other computing devices.

See Also Five stocks we like better than Sandisk Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery

Receive News & Ratings for Sandisk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandisk and related companies with MarketBeat.com's FREE daily email newsletter.

SpaceX (SPCX -1.74%) agreed on Oct. 8 to buy Grain Management's nationwide portfolio of 800 MHz spectrum. The rocket and satellite company says the airwaves will help its Starlink Mobile service reach phones indoors. SpaceX didn't disclose terms, but The Wall Street Journal put the price at around $8 billion in cash.

Investors in the big wireless carriers took the news hard. Shares of T-Mobile US, Verizon, and AT&T each dropped over 10% the next day.

SpaceX stock, though, hardly moved on the news, and it's dipped since. Shares trade near $146 as I write. That puts them about 31% under the record $211.39 close on June 16 and only about 8% over the $135 price set in SpaceX's IPO.

So, does SpaceX's move into the carriers' business make the stock a buy?

Image source: Getty Images.

SpaceX is paying to reach phones indoorsThe deal covers up to 14 megahertz of paired spectrum in the 800 MHz band. SpaceX said it addresses one of the main remaining technical gaps for Starlink Mobile, as a low-band signal like this can go through walls. And the company said most existing phones already support the band.

That same week, the Federal Communications Commission (FCC) cleared SpaceX to launch 15,000 next-generation Starlink Mobile satellites. The Grain purchase itself still needs FCC approval.

Grain just recently bought the airwaves from T-Mobile, in a deal that closed in August, paying $2.9 billion in cash and its own 600 MHz licenses. This makes a direct comparison hard, but the reported price is well over the cash Grain paid.

The purchase comes on top of a bigger one, too. SpaceX is buying 65 MHz of spectrum from EchoStar for around $19.6 billion, a deal it expects to close at the end of November 2027.

Management's thinking on low-band spectrum also looks to have changed fast.

"You don't have to necessarily spend many billions of dollars in low-band spectrum all upfront before you deploy your system," President Gwynne Shotwell said in early August, on SpaceX's call to go over second-quarter results.

Around two months later, SpaceX reportedly agreed to spend about $8 billion on low-band spectrum. I'd say this suggests the company wants its carrier service in place earlier, even at a higher cost.

Starlink is where SpaceX makes moneyShowing why SpaceX keeps investing here, revenue in its connectivity segment (which houses Starlink) rose 66% year over year to $4.3 billion in the second quarter. This was a sharp acceleration from 32% year-over-year growth in the first quarter, when the segment took in $3.3 billion. Operating income for the segment climbed 79% year over year to $1.7 billion.

Of course, that profit's carrying the rest of the company. Connectivity was the only one of SpaceX's three segments to turn an operating profit, while its space and artificial intelligence segments each lost money.

Starlink Mobile is tougher to size. SpaceX doesn't break out its revenue, which is part of enterprise and government sales, and it earns that revenue from revenue-sharing deals with partner carriers like T-Mobile. Owning airwaves could let SpaceX sell service directly. But it could also put SpaceX up against the companies it splits revenue with now.

Shotwell also said on the August call that SpaceX would start flying its next-generation mobile satellites next year and begin service at the end of next year.

SPCX Space Exploration Technologies$146.03-$2.59 (-1.74%)

NASDAQ · As of 4:00 PM ET 10/16/26

Does $8 billion move a $2 trillion stock?Not by itself. At today's price, SpaceX is worth around $2 trillion, and the reported $8 billion is under 1% of that. And the company ended June with $100 billion in cash, cash equivalents, and marketable securities.

The bigger concern for shareholders is the stock's valuation. SpaceX's revenue for the four quarters through June was around $23 billion, leaving the stock at more than 80 times sales. And the company lost $4.8 billion in the first half of 2026. SpaceX posts its third-quarter results after market close on Oct. 20.

Yes, selling phone service directly might become a meaningful new revenue source for Starlink over time. But this revenue is probably more than a year away, and it comes with the cost of building out a network.

In the end, the Grain deal makes Starlink Mobile a more serious rival to the carriers, and their share prices reflected that. For SpaceX shareholders, though, it's a small and far-off addition to a company valued at over 80 times sales. Even after a 31% fall from its peak, the stock looks too pricey to me.

Asset One Wealth Management LLC bought a new position in Microsoft Corporation (NASDAQ:MSFT – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 96,016 shares of the software giant’s stock, valued at approximately $37,987,000. Microsoft comprises about 4.0% of Asset One Wealth Management LLC’s portfolio, making the stock its 3rd largest position.

Other hedge funds have also added to or reduced their stakes in the company. Auto Owners Insurance Co grew its holdings in Microsoft by 56,160.8% during the 4th quarter. Auto Owners Insurance Co now owns 60,116,384 shares of the software giant’s stock worth $29,073,486,000 after acquiring an additional 60,009,531 shares during the period. Amundi raised its position in shares of Microsoft by 30.8% during the first quarter. Amundi now owns 41,675,076 shares of the software giant’s stock worth $15,426,862,000 after purchasing an additional 9,814,598 shares during the period. Dimensional Fund Advisors LP raised its holdings in Microsoft by 10.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 29,323,744 shares of the software giant’s stock worth $10,852,884,000 after buying an additional 2,784,809 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in Microsoft by 64.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 24,264,779 shares of the software giant’s stock valued at $8,982,083,000 after acquiring an additional 9,493,778 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its position in shares of Microsoft by 7.8% during the fourth quarter. Hsbc Holdings PLC now owns 22,138,798 shares of the software giant’s stock worth $10,715,379,000 after buying an additional 1,599,412 shares during the period. Institutional investors own 71.13% of the company’s stock.

Insider Activity In other news, EVP Amy Hood sold 41,674 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $498.27, for a total value of $20,764,903.98. Following the transaction, the executive vice president owned 533,624 shares in the company, valued at approximately $265,888,830.48. The trade was a 7.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Satya Nadella sold 86,525 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $501.46, for a total transaction of $43,388,826.50. Following the sale, the chief executive officer directly owned 486,763 shares in the company, valued at $244,092,173.98. This trade represents a 15.09% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 150,314 shares of company stock worth $75,404,992 in the last 90 days. 0.03% of the stock is owned by company insiders.

Analyst Ratings Changes MSFT has been the subject of several recent research reports. BMO Capital Markets assumed coverage on shares of Microsoft in a report on Monday, October 5th. They set an “outperform” rating for the company. Bank of America raised their price target on Microsoft from $500.00 to $600.00 and gave the company a “buy” rating in a report on Tuesday, September 1st. Weiss Ratings upgraded Microsoft from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Benchmark restated a “buy” rating on shares of Microsoft in a research note on Friday, July 24th. Finally, Oppenheimer increased their price target on Microsoft from $515.00 to $570.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 22nd. Forty-two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $589.71. Get Our Latest Analysis on MSFT

Microsoft News Roundup Here are the key news stories impacting Microsoft this week:

Positive Sentiment: Analysts expect Microsoft to remain the only major hyperscaler with positive free cash flow over the next year despite heavy AI investment. This reinforces confidence that the company can fund data-center expansion without substantial external financing. Microsoft Free Cash Flow Expected to Remain Positive Positive Sentiment: Microsoft signed a 20-year agreement with NiSource for approximately 1,100 megawatts of power for an Indiana data-center campus beginning in 2028. Securing electricity supports future Azure capacity as grid constraints become a bottleneck for AI expansion. Microsoft Signs Power Deal With NiSource Positive Sentiment: Microsoft’s custom Maia AI chips and reports that a new model achieved comparable or better performance than OpenAI’s system using a fraction of the computing power could eventually reduce reliance on expensive third-party GPUs and improve AI economics. Microsoft Wants to Make AI Cheaper Neutral Sentiment: Investors are focused on Azure growth, Copilot adoption, AI monetization and capital expenditures ahead of earnings. Strong demand could support the shares, but the market wants evidence that revenue growth is translating into sustainable margins. Negative Sentiment: The U.K. Competition and Markets Authority is investigating Microsoft’s grip on business software and says Microsoft and Amazon Web Services may need to do more to address cloud-service barriers. Potential remedies could increase compliance costs or weaken customer-lock-in advantages. UK Regulator Targets Microsoft’s Business Software Grip Negative Sentiment: Questions remain over whether custom chips will deliver meaningful savings: AI infrastructure, power and data-center commitments are rising rapidly, while Microsoft is reportedly seeking substantial cost reductions in Azure. That creates concern about near-term free-cash-flow and margin pressure. Microsoft Stock Down 1.9% Shares of MSFT opened at $529.05 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.22 and a current ratio of 1.23. The stock has a market capitalization of $3.93 trillion, a price-to-earnings ratio of 29.46, a PEG ratio of 1.70 and a beta of 1.10. Microsoft Corporation has a 52 week low of $349.20 and a 52 week high of $553.72. The stock has a fifty day moving average of $505.53 and a 200-day moving average of $440.59.

Microsoft (NASDAQ:MSFT – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The software giant reported $4.74 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.50. Microsoft had a return on equity of 31.98% and a net margin of 40.31%. The company had revenue of $90.01 billion for the quarter, compared to analysts’ expectations of $87.62 billion. During the same period in the previous year, the business posted $3.65 earnings per share. The business’s quarterly revenue was up 17.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Microsoft Corporation will post 19.65 earnings per share for the current fiscal year.

Microsoft Increases Dividend The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Thursday, November 19th will be paid a $0.98 dividend. The ex-dividend date of this dividend is Thursday, November 19th. This is a positive change from Microsoft’s previous quarterly dividend of $0.91. This represents a $3.92 annualized dividend and a dividend yield of 0.7%. Microsoft’s payout ratio is currently 20.27%.

About Microsoft (Free Report)

Microsoft Corporation (NASDAQ:MSFT) is a global technology company that develops software, cloud services, devices and digital platforms. Its products and services are used by consumers, businesses, governments and educational institutions worldwide.

The company’s principal offerings include the Windows operating system; Microsoft 365 productivity applications such as Word, Excel, Teams and Outlook; Azure cloud computing and infrastructure services; Dynamics business applications; and enterprise security solutions.

See Also Five stocks we like better than Microsoft Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery

Receive News & Ratings for Microsoft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microsoft and related companies with MarketBeat.com's FREE daily email newsletter.

Dearborn Partners LLC bought a new stake in shares of Microsoft Corporation (NASDAQ:MSFT – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 190,461 shares of the software giant’s stock, valued at approximately $70,503,000. Microsoft accounts for 3.8% of Dearborn Partners LLC’s portfolio, making the stock its 2nd biggest holding.

Several other institutional investors and hedge funds have also bought and sold shares of MSFT. Strategic Wealth Advisors LLC grew its holdings in shares of Microsoft by 1.7% in the second quarter. Strategic Wealth Advisors LLC now owns 1,473 shares of the software giant’s stock worth $549,000 after purchasing an additional 24 shares during the last quarter. Friedenthal Financial increased its stake in shares of Microsoft by 6.2% in the first quarter. Friedenthal Financial now owns 431 shares of the software giant’s stock worth $160,000 after buying an additional 25 shares during the period. Sequent Planning LLC increased its stake in shares of Microsoft by 0.7% in the first quarter. Sequent Planning LLC now owns 3,733 shares of the software giant’s stock worth $1,382,000 after buying an additional 25 shares during the period. Lee Johnson Capital Management LLC increased its stake in shares of Microsoft by 3.8% in the second quarter. Lee Johnson Capital Management LLC now owns 687 shares of the software giant’s stock worth $256,000 after buying an additional 25 shares during the period. Finally, Riverpoint Wealth Management Holdings LLC increased its stake in shares of Microsoft by 0.5% in the first quarter. Riverpoint Wealth Management Holdings LLC now owns 5,543 shares of the software giant’s stock worth $2,052,000 after buying an additional 26 shares during the period. 71.13% of the stock is currently owned by institutional investors.

Insider Activity at Microsoft In other Microsoft news, CEO Judson Althoff sold 10,000 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $487.89, for a total transaction of $4,878,900.00. Following the transaction, the chief executive officer directly owned 100,447 shares of the company’s stock, valued at approximately $49,007,086.83. The trade was a 9.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Amy Hood sold 7,305 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $545.42, for a total transaction of $3,984,293.10. Following the transaction, the executive vice president directly owned 555,396 shares in the company, valued at approximately $302,924,086.32. The trade was a 1.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 150,314 shares of company stock worth $75,404,992. 0.03% of the stock is currently owned by insiders.

Microsoft Price Performance Shares of MSFT stock opened at $529.05 on Friday. The firm has a market cap of $3.93 trillion, a P/E ratio of 29.46, a P/E/G ratio of 1.70 and a beta of 1.10. Microsoft Corporation has a fifty-two week low of $349.20 and a fifty-two week high of $553.72. The business’s 50 day moving average price is $505.53 and its 200-day moving average price is $440.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.22 and a current ratio of 1.23. Microsoft (NASDAQ:MSFT – Get Free Report) last posted its earnings results on Wednesday, July 29th. The software giant reported $4.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.50. The firm had revenue of $90.01 billion for the quarter, compared to analysts’ expectations of $87.62 billion. Microsoft had a return on equity of 31.98% and a net margin of 40.31%. The business’s revenue was up 17.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.65 earnings per share. On average, equities research analysts anticipate that Microsoft Corporation will post 19.65 earnings per share for the current year.

Microsoft Increases Dividend The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Thursday, November 19th will be issued a $0.98 dividend. This represents a $3.92 annualized dividend and a yield of 0.7%. This is an increase from Microsoft’s previous quarterly dividend of $0.91. The ex-dividend date is Thursday, November 19th. Microsoft’s dividend payout ratio (DPR) is presently 20.27%.

Microsoft News Roundup Here are the key news stories impacting Microsoft this week:

Positive Sentiment: Analysts expect Microsoft to remain the only major hyperscaler with positive free cash flow over the next year despite heavy AI investment. This reinforces confidence that the company can fund data-center expansion without substantial external financing. Microsoft Free Cash Flow Expected to Remain Positive Positive Sentiment: Microsoft signed a 20-year agreement with NiSource for approximately 1,100 megawatts of power for an Indiana data-center campus beginning in 2028. Securing electricity supports future Azure capacity as grid constraints become a bottleneck for AI expansion. Microsoft Signs Power Deal With NiSource Positive Sentiment: Microsoft’s custom Maia AI chips and reports that a new model achieved comparable or better performance than OpenAI’s system using a fraction of the computing power could eventually reduce reliance on expensive third-party GPUs and improve AI economics. Microsoft Wants to Make AI Cheaper Neutral Sentiment: Investors are focused on Azure growth, Copilot adoption, AI monetization and capital expenditures ahead of earnings. Strong demand could support the shares, but the market wants evidence that revenue growth is translating into sustainable margins. Negative Sentiment: The U.K. Competition and Markets Authority is investigating Microsoft’s grip on business software and says Microsoft and Amazon Web Services may need to do more to address cloud-service barriers. Potential remedies could increase compliance costs or weaken customer-lock-in advantages. UK Regulator Targets Microsoft’s Business Software Grip Negative Sentiment: Questions remain over whether custom chips will deliver meaningful savings: AI infrastructure, power and data-center commitments are rising rapidly, while Microsoft is reportedly seeking substantial cost reductions in Azure. That creates concern about near-term free-cash-flow and margin pressure. Analyst Upgrades and Downgrades A number of research firms recently commented on MSFT. BNP Paribas Exane lowered shares of Microsoft from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $600.00 price target on shares of Microsoft in a report on Monday, October 12th. Morgan Stanley lowered shares of Microsoft from an “overweight” rating to a “negative” rating in a report on Monday, October 5th. TD Cowen boosted their price objective on shares of Microsoft from $540.00 to $625.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Sanford C. Bernstein set a $660.00 price objective on shares of Microsoft in a research note on Monday, August 10th. Forty-two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Microsoft currently has a consensus rating of “Moderate Buy” and an average price target of $589.71.

View Our Latest Analysis on MSFT

Microsoft Profile (Free Report)

Microsoft Corporation (NASDAQ:MSFT) is a global technology company that develops software, cloud services, devices and digital platforms. Its products and services are used by consumers, businesses, governments and educational institutions worldwide.

The company’s principal offerings include the Windows operating system; Microsoft 365 productivity applications such as Word, Excel, Teams and Outlook; Azure cloud computing and infrastructure services; Dynamics business applications; and enterprise security solutions.

Further Reading Five stocks we like better than Microsoft Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery Want to see what other hedge funds are holding MSFT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Microsoft Corporation (NASDAQ:MSFT – Free Report).

Receive News & Ratings for Microsoft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microsoft and related companies with MarketBeat.com's FREE daily email newsletter.

Castlefield Investment Partners LLP purchased a new position in Microsoft Corporation (NASDAQ:MSFT – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,139 shares of the software giant’s stock, valued at approximately $7,139,000. Microsoft makes up about 4.8% of Castlefield Investment Partners LLP’s holdings, making the stock its 5th largest position.

A number of other institutional investors also recently bought and sold shares of MSFT. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in Microsoft by 4.0% during the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 229,490 shares of the software giant’s stock valued at $85,604,000 after buying an additional 8,773 shares during the period. Markel Group Inc. boosted its holdings in shares of Microsoft by 0.4% during the 1st quarter. Markel Group Inc. now owns 537,630 shares of the software giant’s stock valued at $199,014,000 after buying an additional 1,950 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Microsoft by 8.4% in the 1st quarter. Bessemer Group Inc. now owns 6,921,677 shares of the software giant’s stock worth $2,562,197,000 after buying an additional 537,634 shares during the period. Taylor Securities Services Inc. purchased a new stake in shares of Microsoft in the 4th quarter worth about $2,616,000. Finally, Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Microsoft by 138.8% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,356,359 shares of the software giant’s stock worth $502,077,000 after buying an additional 788,297 shares during the period. 71.13% of the stock is owned by institutional investors.

Insider Activity In related news, CEO Satya Nadella sold 86,525 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $501.46, for a total value of $43,388,826.50. Following the completion of the transaction, the chief executive officer directly owned 486,763 shares in the company, valued at $244,092,173.98. The trade was a 15.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Takeshi Numoto sold 4,810 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $496.48, for a total value of $2,388,068.80. Following the completion of the transaction, the executive vice president directly owned 42,677 shares in the company, valued at $21,188,276.96. This trade represents a 10.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 150,314 shares of company stock valued at $75,404,992 in the last quarter. Insiders own 0.03% of the company’s stock.

Microsoft News Roundup Here are the key news stories impacting Microsoft this week: Positive Sentiment: Analysts expect Microsoft to remain the only major hyperscaler with positive free cash flow over the next year despite heavy AI investment. This reinforces confidence that the company can fund data-center expansion without substantial external financing. Microsoft Free Cash Flow Expected to Remain Positive Positive Sentiment: Microsoft signed a 20-year agreement with NiSource for approximately 1,100 megawatts of power for an Indiana data-center campus beginning in 2028. Securing electricity supports future Azure capacity as grid constraints become a bottleneck for AI expansion. Microsoft Signs Power Deal With NiSource Positive Sentiment: Microsoft’s custom Maia AI chips and reports that a new model achieved comparable or better performance than OpenAI’s system using a fraction of the computing power could eventually reduce reliance on expensive third-party GPUs and improve AI economics. Microsoft Wants to Make AI Cheaper Neutral Sentiment: Investors are focused on Azure growth, Copilot adoption, AI monetization and capital expenditures ahead of earnings. Strong demand could support the shares, but the market wants evidence that revenue growth is translating into sustainable margins. Negative Sentiment: The U.K. Competition and Markets Authority is investigating Microsoft’s grip on business software and says Microsoft and Amazon Web Services may need to do more to address cloud-service barriers. Potential remedies could increase compliance costs or weaken customer-lock-in advantages. UK Regulator Targets Microsoft’s Business Software Grip Negative Sentiment: Questions remain over whether custom chips will deliver meaningful savings: AI infrastructure, power and data-center commitments are rising rapidly, while Microsoft is reportedly seeking substantial cost reductions in Azure. That creates concern about near-term free-cash-flow and margin pressure. Microsoft Stock Down 1.9% NASDAQ:MSFT opened at $529.05 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.22 and a current ratio of 1.23. The firm has a market cap of $3.93 trillion, a P/E ratio of 29.46, a P/E/G ratio of 1.70 and a beta of 1.10. Microsoft Corporation has a fifty-two week low of $349.20 and a fifty-two week high of $553.72. The firm has a 50-day simple moving average of $505.53 and a two-hundred day simple moving average of $440.59.

Microsoft (NASDAQ:MSFT – Get Free Report) last issued its earnings results on Wednesday, July 29th. The software giant reported $4.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.50. The firm had revenue of $90.01 billion for the quarter, compared to the consensus estimate of $87.62 billion. Microsoft had a net margin of 40.31% and a return on equity of 31.98%. The business’s revenue was up 17.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.65 earnings per share. Analysts predict that Microsoft Corporation will post 19.65 earnings per share for the current fiscal year.

Microsoft Increases Dividend The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Thursday, November 19th will be given a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a dividend yield of 0.7%. This is an increase from Microsoft’s previous quarterly dividend of $0.91. The ex-dividend date of this dividend is Thursday, November 19th. Microsoft’s payout ratio is 20.27%.

Analysts Set New Price Targets Several research analysts recently issued reports on MSFT shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $640.00 price target on shares of Microsoft in a research note on Thursday, July 30th. BMO Capital Markets assumed coverage on shares of Microsoft in a research note on Monday, October 5th. They set an “outperform” rating on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $600.00 price objective on shares of Microsoft in a report on Monday, October 12th. Argus cut their price objective on shares of Microsoft from $620.00 to $510.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Finally, Guggenheim reaffirmed a “buy” rating and set a $586.00 target price on shares of Microsoft in a research note on Monday, July 27th. Forty-two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $589.71.

Read Our Latest Report on Microsoft

Microsoft Profile (Free Report)

Microsoft Corporation (NASDAQ:MSFT) is a global technology company that develops software, cloud services, devices and digital platforms. Its products and services are used by consumers, businesses, governments and educational institutions worldwide.

The company’s principal offerings include the Windows operating system; Microsoft 365 productivity applications such as Word, Excel, Teams and Outlook; Azure cloud computing and infrastructure services; Dynamics business applications; and enterprise security solutions.

See Also Five stocks we like better than Microsoft Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery Want to see what other hedge funds are holding MSFT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Microsoft Corporation (NASDAQ:MSFT – Free Report).

Receive News & Ratings for Microsoft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microsoft and related companies with MarketBeat.com's FREE daily email newsletter.